US20140275160A1 - Combination therapy - Google Patents
Combination therapy Download PDFInfo
- Publication number
- US20140275160A1 US20140275160A1 US14/213,940 US201414213940A US2014275160A1 US 20140275160 A1 US20140275160 A1 US 20140275160A1 US 201414213940 A US201414213940 A US 201414213940A US 2014275160 A1 US2014275160 A1 US 2014275160A1
- Authority
- US
- United States
- Prior art keywords
- group
- compound
- composition
- hydrogen
- prostaglandin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CC.CC.[1*]N([2*])*C(=O)CC1=CC=C2C=NC=CC2=C1 Chemical compound CC.CC.[1*]N([2*])*C(=O)CC1=CC=C2C=NC=CC2=C1 0.000 description 11
- XQFCQKMLUAYULB-UHFFFAOYSA-N BC([Y]COC)C(=O)CC1=CC=C2C=NC=CC2=C1.CC.CC Chemical compound BC([Y]COC)C(=O)CC1=CC=C2C=NC=CC2=C1.CC.CC XQFCQKMLUAYULB-UHFFFAOYSA-N 0.000 description 3
- PEUUESBQJHCOEX-OUJCILLJSA-N CC1=CC=CC(OC[C@H](O)/C=C/[C@@H]2C(C/C=C\CCCC(=O)OCC3=CC=C(C(CN)C(=O)CC4=CC=C5C=NC=CC5=C4)C=C3)[C@@H](O)C[C@H]2O)=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\CC2[C@@H](O)C[C@@H](O)[C@@H]2/C=C/[C@@H](O)COC2=CC(C)=CC=C2)C=C1.ClCCl Chemical compound CC1=CC=CC(OC[C@H](O)/C=C/[C@@H]2C(C/C=C\CCCC(=O)OCC3=CC=C(C(CN)C(=O)CC4=CC=C5C=NC=CC5=C4)C=C3)[C@@H](O)C[C@H]2O)=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\CC2[C@@H](O)C[C@@H](O)[C@@H]2/C=C/[C@@H](O)COC2=CC(C)=CC=C2)C=C1.ClCCl PEUUESBQJHCOEX-OUJCILLJSA-N 0.000 description 2
- XXEHOMCWFJIYNP-JIXYJIJASA-N CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCCCCCC2[C@@H](O)C[C@@H](O)[C@@H]2CC[C@@H](O)C2=CC3=C(C=CC=C3)S2)C=C1.C[Si](C)(C)C.NCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCCCCCC2[C@@H](O)C[C@@H](O)[C@@H]2CC[C@@H](O)C2=CC3=C(C=CC=C3)S2)C=C1 Chemical compound CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCCCCCC2[C@@H](O)C[C@@H](O)[C@@H]2CC[C@@H](O)C2=CC3=C(C=CC=C3)S2)C=C1.C[Si](C)(C)C.NCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCCCCCC2[C@@H](O)C[C@@H](O)[C@@H]2CC[C@@H](O)C2=CC3=C(C=CC=C3)S2)C=C1 XXEHOMCWFJIYNP-JIXYJIJASA-N 0.000 description 2
- IWRJBJLCYRZUIQ-FGZNOECHSA-N C.C.CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(CO)C=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\CC2[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]2/C=C/[C@H](COC2=CC(C)=CC=C2)O[Si](C)(C)C(C)(C)C)C=C1.CO.COC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC(C(F)(F)F)=CC=C1.COC(=O)CCC/C=C\C[C@H]1[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](C)[C@@H]1/C=C/[C@@H](O)COC1=CC(C(F)(F)F)=CC=C1.C[C@@H]1C[C@H](O[Si](C)(C)C(C)(C)C)[C@H](C/C=C\CCCC(=O)O)[C@H]1/C=C/[C@@H](O)COC1=CC(C(F)(F)F)=CC=C1.O.O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC(C(F)(F)F)=CC=C1.[Li][OH2+] Chemical compound C.C.CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(CO)C=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\CC2[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]2/C=C/[C@H](COC2=CC(C)=CC=C2)O[Si](C)(C)C(C)(C)C)C=C1.CO.COC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC(C(F)(F)F)=CC=C1.COC(=O)CCC/C=C\C[C@H]1[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](C)[C@@H]1/C=C/[C@@H](O)COC1=CC(C(F)(F)F)=CC=C1.C[C@@H]1C[C@H](O[Si](C)(C)C(C)(C)C)[C@H](C/C=C\CCCC(=O)O)[C@H]1/C=C/[C@@H](O)COC1=CC(C(F)(F)F)=CC=C1.O.O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC(C(F)(F)F)=CC=C1.[Li][OH2+] IWRJBJLCYRZUIQ-FGZNOECHSA-N 0.000 description 1
- VRMWODSYUJLPDQ-LKJCNQOOSA-L CC(C(=O)CC1=CC=C2C(=C1)C=CN=C2O)C1=CSC=C1.CC(C(=O)CC1=CC=C2C(=C1)C=CN=C2O)C1=CSC=C1.CC(C(=O)CC1=CC=C2C(=C1)C=CN=C2O)C1=CSC=C1.CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)[O-].CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O.CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O.CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)[O-].CO.CO.CO.OCCCCCCC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)C1=CC2=C(C=CC=C2)S1.[H]CC(C(=O)CC1=CC=C2C(=C1)C=CN=C2O)C1=CSC=C1.[H]CC(C(=O)CC1=CC=C2C(=C1)C=CN=C2O)C1=CSC=C1 Chemical compound CC(C(=O)CC1=CC=C2C(=C1)C=CN=C2O)C1=CSC=C1.CC(C(=O)CC1=CC=C2C(=C1)C=CN=C2O)C1=CSC=C1.CC(C(=O)CC1=CC=C2C(=C1)C=CN=C2O)C1=CSC=C1.CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)[O-].CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O.CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O.CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)[O-].CO.CO.CO.OCCCCCCC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)C1=CC2=C(C=CC=C2)S1.[H]CC(C(=O)CC1=CC=C2C(=C1)C=CN=C2O)C1=CSC=C1.[H]CC(C(=O)CC1=CC=C2C(=C1)C=CN=C2O)C1=CSC=C1 VRMWODSYUJLPDQ-LKJCNQOOSA-L 0.000 description 1
- URHFSESZEVELKO-PGEVVCQNSA-N CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(CO)C=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCCCCCC2[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]2CC[C@@H](O[Si](C)(C)C(C)(C)C)C2=CC3=C(C=CC=C3)S2)C=C1.CO.COC(=O)CCCCCC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)C1=CC2=C(C=CC=C2)S1.COC(=O)CCCCCC[C@H]1[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](C)[C@@H]1CC[C@@H](C)C1=CC2=C(C=CC=C2)S1.C[C@H](CC[C@H]1[C@H](C)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1CCCCCCC(=O)O)C1=CC2=C(C=CC=C2)S1.C[Si](C)(C)C.O=C(O)CCCCCC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)C1=CC2=C(C=CC=C2)S1 Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(CO)C=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCCCCCC2[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]2CC[C@@H](O[Si](C)(C)C(C)(C)C)C2=CC3=C(C=CC=C3)S2)C=C1.CO.COC(=O)CCCCCC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)C1=CC2=C(C=CC=C2)S1.COC(=O)CCCCCC[C@H]1[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](C)[C@@H]1CC[C@@H](C)C1=CC2=C(C=CC=C2)S1.C[C@H](CC[C@H]1[C@H](C)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1CCCCCCC(=O)O)C1=CC2=C(C=CC=C2)S1.C[Si](C)(C)C.O=C(O)CCCCCC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)C1=CC2=C(C=CC=C2)S1 URHFSESZEVELKO-PGEVVCQNSA-N 0.000 description 1
- KRVGERSZMNCBTI-DJLAIODLSA-N CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F.COC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC(C(F)(F)F)=CC=C1.COC(=O)CCC/C=C\C[C@H]1[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](C)[C@@H]1/C=C/[C@H](COC1=CC(C(F)(F)F)=CC=C1)O[Si](C)(C)C(C)(C)C Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F.COC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC(C(F)(F)F)=CC=C1.COC(=O)CCC/C=C\C[C@H]1[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](C)[C@@H]1/C=C/[C@H](COC1=CC(C(F)(F)F)=CC=C1)O[Si](C)(C)C(C)(C)C KRVGERSZMNCBTI-DJLAIODLSA-N 0.000 description 1
- IXKAQKMUIDTDSO-HBMONEISSA-N CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F.COC(=O)CCCCCC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)C1=CC2=C(C=CC=C2)S1.COC(=O)CCCCCC[C@H]1[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](C)[C@@H]1CC[C@@H](C)C1=CC2=C(C=CC=C2)S1 Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F.COC(=O)CCCCCC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)C1=CC2=C(C=CC=C2)S1.COC(=O)CCCCCC[C@H]1[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](C)[C@@H]1CC[C@@H](C)C1=CC2=C(C=CC=C2)S1 IXKAQKMUIDTDSO-HBMONEISSA-N 0.000 description 1
- NNPPMTNAJDCUHE-UHFFFAOYSA-N CC(C)C Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 1
- IVDZIOSQXJROHK-PAFLOQGTSA-N CC(C)C(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=CC=C1 Chemical compound CC(C)C(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=CC=C1 IVDZIOSQXJROHK-PAFLOQGTSA-N 0.000 description 1
- KWLQLKNMCPXLTL-NQTZGUPLSA-N CC(C)C(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 Chemical compound CC(C)C(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 KWLQLKNMCPXLTL-NQTZGUPLSA-N 0.000 description 1
- FNFRPMZDGMNJLB-BGHCOAIFSA-N CC(C)C(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 Chemical compound CC(C)C(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 FNFRPMZDGMNJLB-BGHCOAIFSA-N 0.000 description 1
- FBANPQVOLALBJO-CBHXRRMGSA-N CC(C)[Si](OS(=O)(=O)C(F)(F)F)(C(C)C)C(C)C.CC(C)[Si](O[C@H]1C[C@@H](C)[C@H](CC[C@H](CCC2=CC=CC=C2)O[Si](C(C)C)(C(C)C)C(C)C)[C@H]1C/C=C\CCCC(=O)O)(C(C)C)C(C)C.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(CO)C=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\CC2[C@@H](O)C[C@@H](O)[C@@H]2CC[C@@H](O)CCC2=CC=CC=C2)C=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\CC2[C@@H](O[Si](C(C)C)(C(C)C)C(C)C)C[C@@H](O[Si](C(C)C)(C(C)C)C(C)C)[C@@H]2CC[C@H](CCC2=CC=CC=C2)O[Si](C(C)C)(C(C)C)C(C)C)C=C1.CO.COC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1.COC(=O)CCC/C=C\C[C@H]1[C@@H](O[Si](C(C)C)(C(C)C)C(C)C)C[C@@H](C)[C@@H]1CC[C@H](CCC1=CC=CC=C1)O[Si](C(C)C)(C(C)C)C(C)C.C[Si](C)(C)C.ClCCl.O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 Chemical compound CC(C)[Si](OS(=O)(=O)C(F)(F)F)(C(C)C)C(C)C.CC(C)[Si](O[C@H]1C[C@@H](C)[C@H](CC[C@H](CCC2=CC=CC=C2)O[Si](C(C)C)(C(C)C)C(C)C)[C@H]1C/C=C\CCCC(=O)O)(C(C)C)C(C)C.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(CO)C=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\CC2[C@@H](O)C[C@@H](O)[C@@H]2CC[C@@H](O)CCC2=CC=CC=C2)C=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\CC2[C@@H](O[Si](C(C)C)(C(C)C)C(C)C)C[C@@H](O[Si](C(C)C)(C(C)C)C(C)C)[C@@H]2CC[C@H](CCC2=CC=CC=C2)O[Si](C(C)C)(C(C)C)C(C)C)C=C1.CO.COC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1.COC(=O)CCC/C=C\C[C@H]1[C@@H](O[Si](C(C)C)(C(C)C)C(C)C)C[C@@H](C)[C@@H]1CC[C@H](CCC1=CC=CC=C1)O[Si](C(C)C)(C(C)C)C(C)C.C[Si](C)(C)C.ClCCl.O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 FBANPQVOLALBJO-CBHXRRMGSA-N 0.000 description 1
- VWYHWTBEIILWMZ-IOCIBGPHSA-N CC(C)[Si](OS(=O)(=O)C(F)(F)F)(C(C)C)C(C)C.COC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1.COC(=O)CCC/C=C\C[C@H]1[C@@H](O[Si](C(C)C)(C(C)C)C(C)C)C[C@@H](C)[C@@H]1CC[C@H](CCC1=CC=CC=C1)O[Si](C(C)C)(C(C)C)C(C)C Chemical compound CC(C)[Si](OS(=O)(=O)C(F)(F)F)(C(C)C)C(C)C.COC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1.COC(=O)CCC/C=C\C[C@H]1[C@@H](O[Si](C(C)C)(C(C)C)C(C)C)C[C@@H](C)[C@@H]1CC[C@H](CCC1=CC=CC=C1)O[Si](C(C)C)(C(C)C)C(C)C VWYHWTBEIILWMZ-IOCIBGPHSA-N 0.000 description 1
- OEPZNHCMMAQXOB-QPRAESTDSA-N CC(C)[Si](O[C@H]1C[C@@H](C)[C@H](CC[C@H](CCC2=CC=CC=C2)O[Si](C(C)C)(C(C)C)C(C)C)[C@H]1C/C=C\CCCC(=O)O)(C(C)C)C(C)C.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(CO)C=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\CC2[C@@H](O[Si](C(C)C)(C(C)C)C(C)C)C[C@@H](O[Si](C(C)C)(C(C)C)C(C)C)[C@@H]2CC[C@H](CCC2=CC=CC=C2)O[Si](C(C)C)(C(C)C)C(C)C)C=C1 Chemical compound CC(C)[Si](O[C@H]1C[C@@H](C)[C@H](CC[C@H](CCC2=CC=CC=C2)O[Si](C(C)C)(C(C)C)C(C)C)[C@H]1C/C=C\CCCC(=O)O)(C(C)C)C(C)C.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(CO)C=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\CC2[C@@H](O[Si](C(C)C)(C(C)C)C(C)C)C[C@@H](O[Si](C(C)C)(C(C)C)C(C)C)[C@@H]2CC[C@H](CCC2=CC=CC=C2)O[Si](C(C)C)(C(C)C)C(C)C)C=C1 OEPZNHCMMAQXOB-QPRAESTDSA-N 0.000 description 1
- INUGVUQFBDNLEQ-FTTXJJDKSA-N CC(C)[Si](O[C@H]1C[C@@H](C)[C@H](CC[C@H](CCC2=CC=CC=C2)O[Si](C(C)C)(C(C)C)C(C)C)[C@H]1C/C=C\CCCC(=O)O)(C(C)C)C(C)C.COC(=O)CCC/C=C\C[C@H]1[C@@H](O[Si](C(C)C)(C(C)C)C(C)C)C[C@@H](C)[C@@H]1CC[C@H](CCC1=CC=CC=C1)O[Si](C(C)C)(C(C)C)C(C)C Chemical compound CC(C)[Si](O[C@H]1C[C@@H](C)[C@H](CC[C@H](CCC2=CC=CC=C2)O[Si](C(C)C)(C(C)C)C(C)C)[C@H]1C/C=C\CCCC(=O)O)(C(C)C)C(C)C.COC(=O)CCC/C=C\C[C@H]1[C@@H](O[Si](C(C)C)(C(C)C)C(C)C)C[C@@H](C)[C@@H]1CC[C@H](CCC1=CC=CC=C1)O[Si](C(C)C)(C(C)C)C(C)C INUGVUQFBDNLEQ-FTTXJJDKSA-N 0.000 description 1
- HMNJFIAHHPAHOQ-KJFVGFCXSA-L CC1=CC=C(C(=O)OCC2=CC=C([C@@H](CN)C(=O)CC3=CC=C4C=NC=CC4=C3)C=C2)C(C)=C1.CC1=CC=C(C(=O)OCC2=CC=C([C@@H](CN)C(=O)CC3=CC=C4C=NC=CC4=C3)C=C2)C(C)=C1.CO.O=C(O)CCCCCC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)C1=CC2=C(C=CC=C2)S1.O=C([O-])CCCCCC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)C1=CC2=C(C=CC=C2)S1.O=C([O-])CCCCCC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)C1=CC2=C(C=CC=C2)S1.[H]CC(C(=O)CC1=CC=C2C(=C1)C=CN=C2O)C1=CSC=C1 Chemical compound CC1=CC=C(C(=O)OCC2=CC=C([C@@H](CN)C(=O)CC3=CC=C4C=NC=CC4=C3)C=C2)C(C)=C1.CC1=CC=C(C(=O)OCC2=CC=C([C@@H](CN)C(=O)CC3=CC=C4C=NC=CC4=C3)C=C2)C(C)=C1.CO.O=C(O)CCCCCC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)C1=CC2=C(C=CC=C2)S1.O=C([O-])CCCCCC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)C1=CC2=C(C=CC=C2)S1.O=C([O-])CCCCCC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)C1=CC2=C(C=CC=C2)S1.[H]CC(C(=O)CC1=CC=C2C(=C1)C=CN=C2O)C1=CSC=C1 HMNJFIAHHPAHOQ-KJFVGFCXSA-L 0.000 description 1
- JNHQZDNWHXBXGB-IZWVXAEQSA-N CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(CO)C=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\CC2[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]2/C=C/[C@H](COC2=CC(C)=CC=C2)O[Si](C)(C)C(C)(C)C)C=C1.C[C@@H]1C[C@H](O[Si](C)(C)C(C)(C)C)[C@H](C/C=C\CCCC(=O)O)[C@H]1/C=C/[C@H](COC1=CC(C(F)(F)F)=CC=C1)O[Si](C)(C)C(C)(C)C Chemical compound CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(CO)C=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\CC2[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]2/C=C/[C@H](COC2=CC(C)=CC=C2)O[Si](C)(C)C(C)(C)C)C=C1.C[C@@H]1C[C@H](O[Si](C)(C)C(C)(C)C)[C@H](C/C=C\CCCC(=O)O)[C@H]1/C=C/[C@H](COC1=CC(C(F)(F)F)=CC=C1)O[Si](C)(C)C(C)(C)C JNHQZDNWHXBXGB-IZWVXAEQSA-N 0.000 description 1
- XCYIPXWMSRSTDU-SLCFNJTRSA-N CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(CO)C=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCCCCCC2[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]2CC[C@@H](O[Si](C)(C)C(C)(C)C)C2=CC3=C(C=CC=C3)S2)C=C1.C[C@H](CC[C@H]1[C@H](C)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1CCCCCCCC(=O)O)C1=CC2=C(C=CC=C2)S1 Chemical compound CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(CO)C=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCCCCCC2[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]2CC[C@@H](O[Si](C)(C)C(C)(C)C)C2=CC3=C(C=CC=C3)S2)C=C1.C[C@H](CC[C@H]1[C@H](C)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1CCCCCCCC(=O)O)C1=CC2=C(C=CC=C2)S1 XCYIPXWMSRSTDU-SLCFNJTRSA-N 0.000 description 1
- ODDUBTIXPQHNDF-JQTXPRAKSA-N CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\CC2[C@@H](O)C[C@@H](O)[C@@H]2/C=C/[C@@H](O)COC2=CC(C)=CC=C2)C=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\CC2[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]2/C=C/[C@H](COC2=CC(C)=CC=C2)O[Si](C)(C)C(C)(C)C)C=C1 Chemical compound CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\CC2[C@@H](O)C[C@@H](O)[C@@H]2/C=C/[C@@H](O)COC2=CC(C)=CC=C2)C=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\CC2[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]2/C=C/[C@H](COC2=CC(C)=CC=C2)O[Si](C)(C)C(C)(C)C)C=C1 ODDUBTIXPQHNDF-JQTXPRAKSA-N 0.000 description 1
- BWBYRNQHKGZSEL-UNVWBGEPSA-N CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\C[C@H]2[C@@H](O)C[C@@H](O)[C@@H]2CC[C@@H](O)CCC2=CC=CC=C2)C=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\C[C@H]2[C@@H](O[Si](C(C)C)(C(C)C)C(C)C)C[C@@H](O[Si](C(C)C)(C(C)C)C(C)C)[C@@H]2CC[C@H](CCC2=CC=CC=C2)O[Si](C(C)C)(C(C)C)C(C)C)C=C1 Chemical compound CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\C[C@H]2[C@@H](O)C[C@@H](O)[C@@H]2CC[C@@H](O)CCC2=CC=CC=C2)C=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\C[C@H]2[C@@H](O[Si](C(C)C)(C(C)C)C(C)C)C[C@@H](O[Si](C(C)C)(C(C)C)C(C)C)[C@@H]2CC[C@H](CCC2=CC=CC=C2)O[Si](C(C)C)(C(C)C)C(C)C)C=C1 BWBYRNQHKGZSEL-UNVWBGEPSA-N 0.000 description 1
- XFTOIIHKOMJPHK-IJXUTEQNSA-N CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\C[C@H]2[C@@H](O)C[C@@H](O)[C@@H]2CC[C@@H](O)CCC2=CC=CC=C2)C=C1.ClCCl.NCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\C[C@H]2[C@@H](O)C[C@@H](O)[C@@H]2CC[C@@H](O)CCC2=CC=CC=C2)C=C1 Chemical compound CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\C[C@H]2[C@@H](O)C[C@@H](O)[C@@H]2CC[C@@H](O)CCC2=CC=CC=C2)C=C1.ClCCl.NCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\C[C@H]2[C@@H](O)C[C@@H](O)[C@@H]2CC[C@@H](O)CCC2=CC=CC=C2)C=C1 XFTOIIHKOMJPHK-IJXUTEQNSA-N 0.000 description 1
- NXUVSGWIEOUXNY-RENTVMLVSA-N CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCCCCCC2[C@@H](O)C[C@@H](O)[C@@H]2CC[C@@H](O)C2=CC3=C(C=CC=C3)S2)C=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCCCCCC2[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]2CC[C@@H](O[Si](C)(C)C(C)(C)C)C2=CC3=C(C=CC=C3)S2)C=C1 Chemical compound CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCCCCCC2[C@@H](O)C[C@@H](O)[C@@H]2CC[C@@H](O)C2=CC3=C(C=CC=C3)S2)C=C1.CCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCCCCCC2[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]2CC[C@@H](O[Si](C)(C)C(C)(C)C)C2=CC3=C(C=CC=C3)S2)C=C1 NXUVSGWIEOUXNY-RENTVMLVSA-N 0.000 description 1
- WGJJROVFWIXTPA-OALUTQOASA-N CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(=O)O Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(=O)O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 1
- VIWGTFZGHXAOAQ-OBRFOQJDSA-N CO.COC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC(C(F)(F)F)=CC=C1.C[Si](C)(C)C.O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC(C(F)(F)F)=CC=C1 Chemical compound CO.COC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC(C(F)(F)F)=CC=C1.C[Si](C)(C)C.O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC(C(F)(F)F)=CC=C1 VIWGTFZGHXAOAQ-OBRFOQJDSA-N 0.000 description 1
- DSEARGMQEGHQJS-XXDCARLQSA-N CO.COC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1.C[Si](C)(C)C.O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 Chemical compound CO.COC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1.C[Si](C)(C)C.O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 DSEARGMQEGHQJS-XXDCARLQSA-N 0.000 description 1
- ASRVXRGXDCWDTM-ZARMPLDUSA-N CO.COC(=O)CCCCCC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)C1=CC2=C(C=CC=C2)S1.C[Si](C)(C)C.O=C(O)CCCCCC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)C1=CC2=C(C=CC=C2)S1 Chemical compound CO.COC(=O)CCCCCC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)C1=CC2=C(C=CC=C2)S1.C[Si](C)(C)C.O=C(O)CCCCCC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)C1=CC2=C(C=CC=C2)S1 ASRVXRGXDCWDTM-ZARMPLDUSA-N 0.000 description 1
- ZHSCDWOHIRYQMK-QFCBNXTISA-N COC(=O)CCC/C=C\C[C@H]1[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](C)[C@@H]1/C=C/[C@H](COC1=CC(C(F)(F)F)=CC=C1)O[Si](C)(C)C(C)(C)C.C[C@@H]1C[C@H](O[Si](C)(C)C(C)(C)C)[C@H](C/C=C\CCCC(=O)O)[C@H]1/C=C/[C@H](COC1=CC(C(F)(F)F)=CC=C1)O[Si](C)(C)C(C)(C)C Chemical compound COC(=O)CCC/C=C\C[C@H]1[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](C)[C@@H]1/C=C/[C@H](COC1=CC(C(F)(F)F)=CC=C1)O[Si](C)(C)C(C)(C)C.C[C@@H]1C[C@H](O[Si](C)(C)C(C)(C)C)[C@H](C/C=C\CCCC(=O)O)[C@H]1/C=C/[C@H](COC1=CC(C(F)(F)F)=CC=C1)O[Si](C)(C)C(C)(C)C ZHSCDWOHIRYQMK-QFCBNXTISA-N 0.000 description 1
- XOVMDPAFCGJGGA-PCBIGNTLSA-N COC(=O)CCCCCC[C@H]1[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](C)[C@@H]1CC[C@@H](C)C1=CC2=C(C=CC=C2)S1.C[C@H](CC[C@H]1[C@H](C)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1CCCCCCC(=O)O)C1=CC2=C(C=CC=C2)S1 Chemical compound COC(=O)CCCCCC[C@H]1[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](C)[C@@H]1CC[C@@H](C)C1=CC2=C(C=CC=C2)S1.C[C@H](CC[C@H]1[C@H](C)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1CCCCCCC(=O)O)C1=CC2=C(C=CC=C2)S1 XOVMDPAFCGJGGA-PCBIGNTLSA-N 0.000 description 1
- KSRNMZVGEYUNEO-JNAAKWLTSA-N COC(CCC/C=C\C[C@H]([C@@H](CC[C@H](CCc1ccccc1)O)[C@@H](C1)O)[C@H]1O)=O Chemical compound COC(CCC/C=C\C[C@H]([C@@H](CC[C@H](CCc1ccccc1)O)[C@@H](C1)O)[C@H]1O)=O KSRNMZVGEYUNEO-JNAAKWLTSA-N 0.000 description 1
- KVNHBYFLUJZIJB-BZWHNQNOSA-N C[C@@H](CCCCCC(OCc1ccc(C(CNC(OC(C)(C)C)=O)C(Nc2ccc(cncc3)c3c2)=O)cc1)=O)C([C@@H](CC[C@H](c1cc(cccc2)c2[s]1)O)[C@@H](C1)O)[C@H]1O Chemical compound C[C@@H](CCCCCC(OCc1ccc(C(CNC(OC(C)(C)C)=O)C(Nc2ccc(cncc3)c3c2)=O)cc1)=O)C([C@@H](CC[C@H](c1cc(cccc2)c2[s]1)O)[C@@H](C1)O)[C@H]1O KVNHBYFLUJZIJB-BZWHNQNOSA-N 0.000 description 1
- AZJGFSJZMLRQBQ-HCHMJIPCSA-N NCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\CC2[C@@H](O)C[C@@H](O)[C@@H]2CC[C@@H](O)CCC2=CC=CC=C2)C=C1 Chemical compound NCC(C(=O)CC1=CC=C2C=NC=CC2=C1)C1=CC=C(COC(=O)CCC/C=C\CC2[C@@H](O)C[C@@H](O)[C@@H]2CC[C@@H](O)CCC2=CC=CC=C2)C=C1 AZJGFSJZMLRQBQ-HCHMJIPCSA-N 0.000 description 1
- HSEBSHBNOZRBIX-IUNQSRQSSA-N NCC(C(Nc1cc2ccncc2cc1)=O)c1ccc(COC(CCCCCCC([C@@H](CC[C@H](c2cc(cccc3)c3[s]2)O)[C@@H](C2)O)[C@H]2O)=O)cc1 Chemical compound NCC(C(Nc1cc2ccncc2cc1)=O)c1ccc(COC(CCCCCCC([C@@H](CC[C@H](c2cc(cccc3)c3[s]2)O)[C@@H](C2)O)[C@H]2O)=O)cc1 HSEBSHBNOZRBIX-IUNQSRQSSA-N 0.000 description 1
- KUINCCADIITPAM-FJGIRIFESA-N NCC(C(Nc1ccc(cncc2)c2c1)=O)c1ccc(COC(CCC/C=C\CC([C@@H](CC[C@H](CCc2ccccc2)O)[C@@H](C2)O)[C@H]2O)=O)cc1 Chemical compound NCC(C(Nc1ccc(cncc2)c2c1)=O)c1ccc(COC(CCC/C=C\CC([C@@H](CC[C@H](CCc2ccccc2)O)[C@@H](C2)O)[C@H]2O)=O)cc1 KUINCCADIITPAM-FJGIRIFESA-N 0.000 description 1
- YFHHIZGZVLHBQZ-KDACTHKWSA-M O=C([O-])CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=CC=C1 Chemical compound O=C([O-])CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=CC=C1 YFHHIZGZVLHBQZ-KDACTHKWSA-M 0.000 description 1
- WWSWYXNVCBLWNZ-QIZQQNKQSA-M O=C([O-])CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 Chemical compound O=C([O-])CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 WWSWYXNVCBLWNZ-QIZQQNKQSA-M 0.000 description 1
- HNPFPERDNWXAGS-NFVOFSAMSA-M O=C([O-])CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 Chemical compound O=C([O-])CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 HNPFPERDNWXAGS-NFVOFSAMSA-M 0.000 description 1
- HNPFPERDNWXAGS-NFVOFSAMSA-N O[C@H](CC[C@H]([C@@H](C/C=C\CCCC(O)=O)[C@H](C1)O)[C@@H]1O)CCc1ccccc1 Chemical compound O[C@H](CC[C@H]([C@@H](C/C=C\CCCC(O)=O)[C@H](C1)O)[C@@H]1O)CCc1ccccc1 HNPFPERDNWXAGS-NFVOFSAMSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- IOP intraocular pressure
- the disclosure may provide a composition comprising:
- the disclosure may provide a compound according to formula (II):
- the disclosure may provide a compound of formula (III):
- the disclosure may provide a composition comprising:
- a prostaglandin selected from the group consisting of latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, latanoprostene bunod, unoprostone, PGF 2 ⁇ and fluprostenol.
- the disclosure may provide a composition comprising:
- a prostaglandin selected from the group consisting of latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, latanoprostene bunod, unoprostone, PGF 2 ⁇ and fluprostenol.
- the disclosure may provide a composition comprising:
- a prostaglandin selected from the group consisting of latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, latanoprostene bunod, unoprostone, PGF 2 ⁇ and fluprostenol.
- the disclosure may provide a composition comprising:
- a prostaglandin selected from the group consisting of latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, latanoprostene bunod, unoprostone, PGF 2 ⁇ and fluprostenol.
- the disclosure may provide a composition comprising:
- a prostaglandin selected from the group consisting of latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, latanoprostene bunod, unoprostone, PGF 2 ⁇ and fluprostenol.
- the disclosure may provide a composition comprising:
- a prostaglandin selected from the group consisting of latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, latanoprostene bunod, unoprostone, PGF 2 ⁇ and fluprostenol.
- the disclosure may provide a method of treating an ocular disorder in a subject in need of treatment, comprising administering to the subject a compound or composition described herein.
- the ocular disorder is glaucoma.
- the disclosure may provide a method of reducing intraocular pressure in a subject in need thereof, comprising topically administering to an eye of the subject a compound or composition described herein.
- FIG. 1 is a graph showing intraocular pressure following administration of compositions described in Example 4.
- FIG. 2 is a graph showing intraocular pressure following administration of compositions described in Example 5.
- compositions that include an isoquinoline compound (e.g., a compound of formula (I)) and a prostaglandin or prostaglandin analog (e.g., latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, latanoprostene bunod, unoprostone, PGF 2 ⁇ or fluprostenol) are described herein.
- an isoquinoline compound e.g., a compound of formula (I)
- a prostaglandin or prostaglandin analog e.g., latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, latanoprostene bunod, unoprostone, PGF 2 ⁇ or fluprostenol
- compounds of formula (II) which include an isoquinoline compound that is covalently linked to a prostaglandin or a prostaglandin analog
- compounds of formula (III) which are salts of an isoquinoline compound and a free acid of a prostaglandin or a prostaglandin analog.
- Such compounds and compositions may be effective for treating ocular disorders such as glaucoma, for example, by lowering intraocular pressure.
- “Acyl” or “carbonyl” refers to the group —C(O)R wherein R is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocyclylalkyl, any of which may be optionally substituted, e.g., with one or more substituents.
- R is alkyl
- such a group may be referred to as an alkylcarbonyl group.
- administering refers to administration of the compounds as needed to achieve a desired effect.
- Alkoxy refers to the group —O—R wherein R is alkyl, alkenyl, alkynyl, cycloalkyl or heterocyclyl, any of which may be optionally substituted, e.g., with one or more substituents.
- Alkyl refers to a saturated aliphatic hydrocarbon chain, which may be straight or branched.
- An alkyl group may have an indicated number of carbon atoms.
- C 1 -C 12 alkyl refers to an alkyl group having from 1 to 12 (inclusive) carbon atoms.
- C 1 -C 4 alkyl refers to an alkyl group having 1, 2, 3 or 4 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl or tert-butyl.
- An alkyl group may be optionally substituted, e.g., with one or more substituents.
- Alkylene refers to a divalent alkyl group, e.g., —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 — or —CH 2 CH(CH 3 )CH 2 —.
- An alkyl or alkylene may be optionally substituted, e.g., with one or more substituents.
- Alkenyl refers to a straight or branched hydrocarbon chain having one or more double bonds.
- An alkenyl group may have an indicated number of carbon atoms.
- C 2 -C 12 alkenyl refers to an alkenyl group having from 2 to 12 (inclusive) carbon atoms.
- C 2 -C 4 alkenyl refers to an alkenyl group having 2, 3 or 4 carbon atoms.
- Examples of alkenyl groups include, but are not limited to, allyl, propenyl, 2-butenyl, 3-hexenyl and 3-octenyl groups.
- One of the double bond carbons may optionally be the point of attachment of the alkenyl substituent.
- alkenylene refers to a divalent alkenyl, e.g., —CH ⁇ CH—, —CH ⁇ CH 2 CH 2 — or —CH ⁇ C ⁇ CH—.
- An alkenyl or alkenylene may be optionally substituted, e.g., with one or more substituents.
- alkynyl refers to a straight or branched hydrocarbon chain having one or more triple bonds.
- An alkynyl group may have an indicated number of carbon atoms.
- C 2 -C 12 alkynyl refers to an alkynyl group having from 2 to 12 (inclusive) carbon atoms.
- C 2 -C 4 alkynyl refers to an alkynyl group having 2, 3 or 4 carbon atoms.
- Examples of alkynyl groups include, but are not limited to, ethynyl, propargyl, and 3-hexynyl.
- One of the triple bond carbons may optionally be the point of attachment of the alkynyl substituent.
- alkynylene refers to a divalent alkynyl, e.g., —C ⁇ C— or —C ⁇ C—CH 2 —.
- An alkynyl or alkynylene may be optionally substituted, e.g., with one or more substituents.
- Amino refers to the group —NR′R′′ wherein R′ and R′′ are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocyclylalkyl, or R′ and R′′, together with the nitrogen to which they are attached, may form a ring.
- amino groups include, but are not limited to, —NH 2 , alkylamino groups such as —NHCH 3 , —NHCH 2 CH 3 and —NHCH(CH 3 ) 2 , dialkylamino groups such as —N(CH 3 ) 2 and —N(CH 2 CH 3 ) 2 , and arylamino groups such as —NHPh.
- alkylamino groups such as —NHCH 3 , —NHCH 2 CH 3 and —NHCH(CH 3 ) 2
- dialkylamino groups such as —N(CH 3 ) 2 and —N(CH 2 CH 3 ) 2
- arylamino groups such as —NHPh.
- cyclic amino groups include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, piperidino, piperazinyl, perhydrodiazepinyl, morpholino, and thiomorpholino.
- the groups R′ and R′′ may be optionally substituted, e.g., with one or more substituents, or when R′ and R′′ together with the nitrogen to which they are attached form a ring, the ring may be optionally substituted, e.g., with one or more substituents.
- AR-102 refers to the compound 3-hydroxy-2,2-bis(hydroxymethyl)propyl7-((1R,2R,3R,5S)-2-((R)-3-(benzo[b]-thiophen-2-yl)-3-hydroxypropyl)-3,5-dihydroxycyclopentyl)heptanoate.
- AR-102 free acid refers to the compound 7-((1R,2R,3R,5S)-2-((R)-3-(benzo[b]thiophen-2-yl)-3-hydroxypropyl)-3,5-dihydroxycyclopentyl)heptanoic acid.
- Aryl refers to an aromatic monocyclic, bicyclic, or tricyclic hydrocarbon ring system, wherein any ring atom capable of substitution can be substituted (e.g., with one or more substituents).
- the substituents may be positioned at various locations on an aryl group.
- substituents on a phenyl group may be located at an ortho-position, a meta-position, the para-position, or combinations thereof.
- Examples of aryl groups include, but are not limited to, phenyl, naphthyl, and anthracenyl.
- Arylalkyl refers to an alkyl group in which an alkyl hydrogen atom is replaced with an aryl group.
- Arylalkyl includes groups in which more than one hydrogen atom has been replaced with an aryl group.
- Examples of arylalkyl groups include but are not limited to benzyl, 2-phenylethyl, 3-phenylpropyl, 9-fluorenyl, benzhydryl, and trityl groups.
- Arylalkyl groups can be optionally substituted, e.g., with one or more substituents on either the alkyl portion or the aryl portion of the arylalkyl group.
- Aryloxy refers to the group —O—R wherein R is aryl or heteroaryl, either of which may be optionally substituted, e.g., with one or more substituents.
- Buffer or “buffer system” refers to a compound or combination of compounds that provide a buffering system in solution that exhibits buffering capacity, that is, the capacity to neutralize, within limits, either acids or bases with relatively little or no change in the original pH.
- buffering capacity is defined to mean the millimoles (mM) of strong acid or base (or respectively, hydrogen or hydroxide ions) required to change the pH by one unit when added to one liter (a standard unit) of the buffer solution.
- the buffer capacity will depend on the type and concentration of the buffer components.
- Carboxyl refers to the group —C( ⁇ O)OR, wherein R is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocyclylalkyl any of which may be optionally substituted, e.g., with one or more substituents.
- Carbonylamino or “amido” refers to the group —C(O)NR′R′′ wherein R′ and R′′ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocyclylalkyl, or R′ and R′′, together with the nitrogen to which they are attached, may form a ring.
- the groups R′ and R′′ may be optionally substituted, e.g., with one or more substituents, or when R′ and R′′ together with the nitrogen to which they are attached form a ring, the ring may be optionally substituted, e.g., with one or more substituents.
- Cycloalkyl refers to nonaromatic, saturated or partially unsaturated monocyclic, bicyclic, tricyclic or polycyclic hydrocarbon groups. Cycloalkyl groups may include about 3 to about 12 carbon atoms. For example, monocyclic cycloalkyl groups may include 3 to 10 carbon atoms, e.g., 3, 4, 5, 6, 7 or 8 carbon atoms. Bicyclic carbocyclic groups contain 8 to 12 carbon atoms, e.g., 9 or 10 carbon atoms. Any ring atom can be substituted (e.g., with one or more substituents). Cycloalkyl groups include fused, spiro, and bridged bicyclic ring systems.
- cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, methylcyclohexyl, adamantyl, norbornyl and norbornenyl.
- Cycloalkylalkyl refers to an alkyl group substituted with a cycloalkyl group.
- Excipient refers to physiologically compatible additives useful in preparation of a pharmaceutical composition.
- Examples of pharmaceutically acceptable carriers and excipients can, for example, be found in Remington Pharmaceutical Science, 16 th Ed.
- Haloalkyl refers to an alkyl group in which one or more hydrogen atoms are replaced with a halogen, and includes alkyl moieties in which all hydrogens have been replaced with halogens (e.g., perfluoroalkyl such as CF 3 ).
- Halogen or “halo” refers to fluoro, chloro, bromo or iodo moieties.
- Heteroalkyl refers to an alkyl group, as defined herein, wherein at least one carbon atom of the alkyl group is replaced with a heteroatom. Suitable heteroalkyl groups include, but are not limited to, methoxymethyl (—CH 2 —O—CH 3 ).
- Heteroaryl or “heteroaromatic” refers to an aromatic monocyclic, bicyclic or tricyclic ring having one or more heteroatoms.
- a heteroaryl group may be an aromatic 5-8 membered monocyclic ring having 1-4 heteroatoms, an 8-12 membered bicyclic ring having 1-6 heteroatoms, or an 11-14 membered tricyclic ring system having 1-9 heteroatoms.
- Heteroaryl groups can contain fused rings, which are rings that share one or more common atoms. Any ring atom capable of substitution can be substituted (e.g., with one or more substituents).
- heteroaryl groups include, but are not limited to, tetrazoylyl, triazolyl, thienyl, thiazolyl, isothiazolyl, purinyl, pyrimidyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, furanyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, indolyl, isoindolyl, indolizinyl, indazolyl, benzimidazolyl, phthalazinyl, pteridinyl, carbazolyl, carbolinyl, phenanthridinyl, acridinyl, phenanthrolinyl, phenazinyl and naphthyridiny
- heteroarylalkyl refers to an alkyl group substituted with a heteroaryl group.
- Heteroatom refers to an atom other than carbon in the ring of a heterocyclic group or a heteroaromatic group or the chain of a heteroalkyl group.
- heteroatoms may be selected from the group consisting of nitrogen, oxygen, silicon, phosphorus and sulfur. Particularly suitable heteroatoms are nitrogen, oxygen and sulfur. Groups containing more than one heteroatom may contain different heteroatoms.
- Heterocyclyl or “heterocycloalkyl” refers to a nonaromatic, saturated or partially unsaturated hydrocarbon ring system containing at least one heteroatom. Heterocyclyl groups may include about 3 to about 12 member atoms. For example, monocyclic cycloalkyl groups may include 3 to 10 member atoms, e.g., 3, 4, 5, 6, 7 or 8 member atoms. Bicyclic carbocyclic groups contain 8 to 12 member atoms, e.g., 9 or 10 member atoms. Any ring atom capable of substitution can be substituted (e.g., with one or more substituents). Heterocyclyl groups include fused, spiro, and bridged bicyclic ring systems.
- heterocyclyl groups include, but are not limited to, epoxy, tetrahydrofuranyl, homopiperidinyl, tetrahydrothienyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, pyrrolinyl, pyrimidinyl, pyrrolidinyl, indolinyl, tetrahydropyridinyl, dihydropyran, thianthrene, pyran, benzopyran, xanthene, phenoxathiin, phenothiazinyl, furazanyl, lactones, lactams such as azetidinones and pyrrolidinones, sultams, sultones, and the like.
- heterocyclylalkyl or “heterocycloalkylalkyl”, as used herein, refers to an alkyl group substituted with a heterocyclyl group.
- “Hydroxy” or “hydroxyl” refers to the group —OH.
- Linker means a chain of n member atoms where n is an integer from 1 to 4.
- Member atom means a carbon, nitrogen, oxygen or sulfur atom. Member atoms may be substituted up to their normal valence.
- mercapto or “thiol” refers to an —SH radical.
- thioalkoxy or “thioether” refers to an —S-alkyl radical.
- thioaryloxy refers to an —S-aryl radical.
- ocular disorder includes, but is not limited to, glaucoma, allergy, cancers of the eye, neurodegenerative diseases of the eye, dry eye, and corneal epithelial damage.
- a “method of treating an ocular disorder” may refer to a method of treating glaucoma, allergy, cancers of the eye, neurodegenerative diseases of the eye, dry eye, and corneal epithelial damage, or may refer to a method of preserving retinal ganglion cells.
- oxo refers to an oxygen atom, which forms a carbonyl when attached to carbon, an N-oxide when attached to nitrogen, and a sulfoxide or sulfone when attached to sulfur.
- thioxo refers to a sulfur atom, which forms a thiocarbonyl when attached to carbon.
- Phosphonate refers to —P(O)(OR) 2 , wherein each R is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocyclylalkyl, each of which may be optionally substituted, e.g., with one or more substituents.
- a “prostaglandin” refers to any compound having a prostanoic acid skeleton:
- prostaglandin analog refers to a compound that has the potential to bind to a prostaglandin receptor.
- Prostaglandin analogs include protected prostaglandins or prostaglandin prodrugs, e.g. prostaglandins with esters or amides at the C1, C9, C11 and/or C15 positions.
- Prostaglandin free acid refers to a prostaglandin or prostaglandin analog that has a carboxylic acid moiety at the C1 position.
- Prostaglandin F analog refers to a compound, generally structurally similar to naturally occurring PGF 2 ⁇ , which has the potential to bind to and activate a prostaglandin F-type receptor.
- F-type receptors include, but are not limited to the FP receptor.
- Prostaglandin E analog “Prostaglandin E analog,” “PGE analog,” “analog of PGE 2 ” or “analog of PGE 1 ” refers to a compound, generally structurally similar to naturally occurring PGE 2 or PGE 1 , which has the potential to bind to and activate a prostaglandin E-type receptor.
- E-type receptors include, but are not limited to the EP1, EP2, EP3 and EP4 receptors.
- Prostaglandin D analog “Prostaglandin D analog,” “PGD analog” or “analog of PGD 2 ” refers to a compound, generally structurally similar to naturally occurring PGD 2 , which has the potential to bind to and activate a prostaglandin D-type receptor.
- D-type receptors include, but are not limited to the DP1 and DP2 receptors.
- Rings means a collection of member atoms that are cyclic. Rings may be carbocyclic, aromatic, or heterocyclic or heteroaromatic, and may be substituted or unsubstituted, and may be saturated or unsaturated. Ring junctions with the main chain may be fused or spirocyclic. Rings may be monocyclic or bicyclic. Rings contain at least 3 member atoms and at most 12 member atoms. Monocyclic rings may contain 3 to 10 member atoms and bicyclic rings may contain from 8 to 12 member atoms. Bicyclic rings themselves may be fused or spirocyclic. Rings may be optionally substituted or unsubstituted, e.g., with one or more substituents.
- ROCKi refers to an inhibitor of a Rho-associated protein kinase (ROCK).
- Substituent refers to a group “substituted” on a group such as an alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl group, at any substitutable atom of that group.
- Suitable substituents include, without limitation: acyl, alkoxy, alkyl, alkenyl, alkynyl, amino, aryl, arylalkyl, carbonylamino, carboxy, cycloalkyl, cycloalkylalkyl, cyano, halo, haloalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, hydroxy, nitro, oxo (e.g., C ⁇ O), phosphonate, sulfinyl, sulfonyl, sulfonate, sulfonamido, thioamido, thiol, thioalkyl, thioxo (e.g., C ⁇ S), and ureido.
- substituents on a group are independently any one single, or any combination of the aforementioned substituents.
- a substituent may itself be substitutedo.
- “Sulfinyl” refers to a —S( ⁇ O)R group, wherein R is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocyclylalkyl, any of which may be optionally substituted (e.g., with one or more substituents).
- “Sulfonyl” refers to a —S(O) 2 R group, wherein R is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocyclylalkyl, any of which may be optionally substituted (e.g., with one or more substituents).
- “Sulfonamido” refers to a —S(O) 2 NR′R′′ group wherein R′ and R′′ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocyclylalkyl, any of which may be optionally substituted (e.g., with one or more substituents).
- “Therapeutically effective amount” refers to a dosage of the compounds or compositions effective for influencing, reducing or inhibiting the activity of or preventing activation of a kinase. This term as used herein may also refer to an amount effective at bringing about a desired in vivo effect in an animal, preferably, a human, such as reduction in intraocular pressure.
- Thioalkyl refers to the group —S-alkyl.
- Thioamido refers to —C(S)NR′R′′ wherein R′ and R′′ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocyclylalkyl, or R′ and R′′ together with the nitrogen to which they are attached, may form a ring.
- the groups R′ and R′′ may be optionally substituted, e.g., with one or more substituents, or when R′ and R′′ together with the nitrogen to which they are attached form a ring, the ring may be optionally substituted, e.g., with one or more substituents.
- Treating refers to administering a regimen to the subject, e.g., the administration a compound or composition described herein, such that the disorder or at least one symptom of the disorder is healed, alleviated, relieved, altered, remedied, ameliorated, and/or improved. Treating includes administering an amount effective to alleviate, relieve, alter, remedy, ameliorate, improve and/or affect the disorder or the symptoms of the disorder. The treatment may inhibit deterioration or worsening of a symptom of a disorder.
- “Ureido” refers to —N(R)C(O)NR′R′′, wherein each R, R′ and R′′ is independently selected from the group consisting selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocyclylalkyl, any of which may be optionally substituted (e.g., with one or more substituents).
- substituent groups are specified by their conventional chemical formulae, written from left to right, they optionally encompass substituents resulting from writing the structure from right to left, e.g., —CH 2 NH— optionally also recites —NHCH 2 —. While certain lists of substituent groups include a group shown in both orientations, it should be expressly understood that any substituent group written in a certain direction (e.g., left to right) also encompasses the same group in the other direction (e.g., right to left).
- groups and substituents thereof may be selected in accordance with permitted valence of the atoms and the substituents, such that the selections and substitutions result in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.
- any numerical range recited herein includes all values from the lower value to the upper value.
- concentration range is stated as 1% to 50%, it is intended that values such as 2% to 40%, 10% to 30%, or 1% to 3%, etc., are expressly enumerated in this specification.
- values such as 2% to 40%, 10% to 30%, or 1% to 3%, etc., are expressly enumerated in this specification.
- Compounds that may be used in compositions described herein include isoquinoline compounds. Such compounds and the compositions including them may have kinase inhibitory activity and thus may be useful in influencing or inhibiting the action of kinases, and in treatment and/or prevention of diseases or conditions influenced by kinases.
- Exemplary kinases that may be influenced include, but are not limited to, ROCK-I, ROCK-II, PKA, PKC, CAM Kinases, GRK-2, GRK-3, GRK-5 or GRK-6.
- the kinase inhibited may be a Rho-associated protein kinase (ROCK).
- Isoquinoline compounds that may be used in compositions and methods described herein include compounds of formula (I):
- X 1 is hydrogen, X 2 is hydroxy, R 1 is alkyl (e.g., methyl), R 2 is alkyl (e.g., methyl), A is —CH(R 10 )—, and R 10 is aryl (e.g., phenyl).
- X 1 is hydrogen
- X 2 is hydroxy
- R 1 and R 2 together form a heterocyclyl ring
- A is —CH(R 10 )—
- R 10 is alkyl
- X 1 and X 2 are hydrogen, R 1 is alkyl (e.g., methyl), and R 2 is alkyl (e.g., methyl), A is —CH(R 10 )—, and R 10 is heteroaryl (e.g., thienyl).
- X 1 and X 2 are hydrogen, R 1 is hydrogen, and R 2 is hydrogen, A is —CH 2 CH(R 10 )—, and R 10 is a substituted aryl group.
- X 1 is hydrogen, X 2 is hydroxy, R 1 is alkyl (e.g., methyl), R 2 is alkyl (e.g., methyl), A is —CH(R 10 )—, and R 10 is heteroaryl (e.g., thienyl).
- X 1 and X 2 are hydrogen, R 1 is alkyl (e.g., methyl), and R 2 is hydrogen, A is —CH(R 10 )—, and R 10 is heteroaryl (e.g., thienyl).
- Isoquinoline compounds that may be used in compositions and methods described herein include compounds of formula (Ia) which is the same as its tautomeric form, also shown here for clarification purposes:
- R 10 is aryl (e.g., phenyl). In some embodiments, R 10 is heteroaryl (e.g., thienyl). In some embodiments, R 1 and R 2 are independently selected from the group consisting of hydrogen and methyl, or R 1 and R 2 are taken together with the nitrogen to which they are attached to form a heterocyclyl ring (e.g., pyrrolidone or piperidine).
- a heterocyclyl ring e.g., pyrrolidone or piperidine.
- Isoquinoline compounds that may be used in compositions and methods described herein include compounds of formula (Ib):
- R 10 is aryl (e.g., phenyl). In some embodiments, R 10 is aryl (e.g., phenyl) substituted with —CH 2 —OC(O)—R a , wherein R a is optionally substituted aryl (e.g., phenyl, e.g., 2,4-dimethylphenyl). In some embodiments, R 1 and R 2 are independently selected from the group consisting of hydrogen and methyl, or R 1 and R 2 are taken together with the nitrogen to which they are attached to form a heterocyclyl ring (e.g., pyrrolidone or piperidine).
- a heterocyclyl ring e.g., pyrrolidone or piperidine
- the compound of formula (I) may be selected from the group consisting of:
- Such compounds include compounds of formula (II):
- acyl radical of a prostaglandin or a prostaglandin analog refers to a prostaglandin or a prostaglandin analog in which the Cl position has the group —C(O)—.
- acyl radicals of latanoprost, bimatoprost and travoprost are illustrated below:
- X 1 and X 2 are hydrogen
- B is —CH 2 NR 1 R 2
- R 1 is alkyl (e.g., methyl)
- R 2 is alkyl (e.g., methyl)
- PG is the acyl radical of latanoprost.
- X 1 and X 2 are hydrogen
- B is —CH 2 NR 1 R 2
- R 1 and R 2 are hydrogen
- PG is the acyl radical of latanoprost.
- X 1 is hydrogen
- X 2 is hydroxy
- B is —CH 2 NR 1 R 2
- R 1 and R 2 are hydrogen
- PG is the acyl radical of latanoprost.
- X 1 is hydrogen
- X 2 is hydroxy
- B is —NR 1 R 2
- R 1 is hydrogen
- R 2 is hydrogen
- PG is the acyl radical of travoprost.
- X 1 is hydrogen
- X 2 is hydroxy
- B is —NR 1 R 2
- R 1 is alkyl (e.g., methyl)
- R 2 is alkyl (e.g., methyl)
- PG is the acyl radical of latanoprost.
- X 1 and X 2 are hydrogen
- B is —CH 2 NR 1 R 2
- R 1 is hydrogen
- R 2 is hydrogen
- PG is the acyl radical of travoprost.
- X 1 and X 2 are hydrogen
- B is —CH 2 NR 1 R 2
- R 1 is hydrogen
- R 2 is hydrogen
- PG is the acyl radical of bimatoprost.
- PG is the acyl radical of latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, latanoprostene bunod, unoprostone, PGF 2 ⁇ or fluprostenol.
- Step (a) may be conducted in a suitable solvent and in the presence of a suitable coupling agent, such as a carbodiimide. Following coupling in step (a), the product may be deprotected in step (b) using methods particular to the protecting groups that were used.
- Such compounds include compounds of formula (III):
- compositions and methods described herein also include salts of isoquinoline compounds and prostaglandin free acids.
- Such compounds include compounds of formula (III):
- a “deprotonated free acid of a prostaglandin or a prostaglandin analog” refers to a prostaglandin or a prostaglandin analog in which the C1 position has the group —C(O)O—.
- deprotonated free acids of latanoprost, bimatoprost and travoprost are illustrated below:
- X 1 is hydrogen
- X 2 is hydroxy
- R 1 is alkyl (e.g., methyl)
- R 2 is alkyl (e.g., methyl)
- A is —CH(R 10 )—
- R 10 is aryl (e.g., phenyl).
- X 1 is hydrogen
- X 2 is hydroxy
- R 1 and R 2 together form a heterocyclyl ring
- A is —CH(R 10 )—
- R 10 is alkyl
- X 1 and X 2 are hydrogen, R 1 is alkyl (e.g., methyl), and R 2 is alkyl (e.g., methyl), A is —CH(R 10 )—, and R 10 is heteroaryl (e.g., thienyl).
- X 1 and X 2 are hydrogen, R 1 is hydrogen, and R 2 is hydrogen, A is —CH 2 CH(R 10 )—, and R 10 is a substituted aryl group.
- X 1 is hydrogen
- X 2 is hydroxy
- R 1 is alkyl (e.g., methyl)
- R 2 is alkyl (e.g., methyl)
- A is —CH(R 10 )—
- R 10 is heteroaryl (e.g., thienyl).
- X 1 and X 2 are hydrogen, R 1 is alkyl (e.g., methyl), and R 2 is hydrogen, A is —CH(R 10 )—, and R 10 is heteroaryl (e.g., thienyl).
- PG e is a deprotonated free acid of latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, latanoprostene bunod, unoprostone, PGE 1 , PGF 2 ⁇ or fluprostenol.
- Compounds of formula (III) may be synthesized by combining a prostaglandin free acid and an isoquinoline compound, e.g., in a suitable solvent.
- the starting materials may be combined in an approximately 1:1 ratio.
- the mixture may be heated to promote dissolution of the starting materials if necessary.
- the solvent can then be removed to provide the salt compound.
- compositions described herein may include a prostaglandin or a prostaglandin analog.
- a prostaglandin or a prostaglandin analog may comprise a compound of formula (IV):
- no carbon atom in a compound of formula (IV) has two or more heteroatoms attached to it unless the two or more heteroatoms are member atoms in a heteroaromatic ring system.
- the relative stereochemistry at C8, C9, and C12 is as specified. That is, the bond between C7 and C8 is in the a orientation, the alcohol (protected or unprotected) at C9 is in the ⁇ orientation, and the bond between C12 and C13 is in the ⁇ orientation.
- the invention also includes optical isomers, diastereomers and enantiomers of the above structure. At all stereocenters where stereochemistry is not defined (e.g. C11 and C15), both epimers are envisioned. In some embodiments, stereochemistry at all such stereocenters of the invention mimic that of naturally occurring PGF 2 ⁇ .
- Q1 is either H or an alcohol protecting group and Q2 and Q3 are alcohol protecting groups. In other embodiments, Q1, Q2, and Q3 are all alcohol protecting groups and may be different alcohol protecting groups and may be the same alcohol protecting group.
- Exemplary prostaglandins and prostaglandin analogs include latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, latanoprostene bunod, unoprostone, PGE 1 , PGF 2 ⁇ and fluprostenol.
- prostaglandins and related compounds suitable for use in compositions of the disclosure include, but are not limited to, those found in the following patents and patent applications, which are incorporated herein by reference.
- Compounds described herein may exist in one or more particular geometric, optical, enantiomeric, diastereomeric, epimeric, atropic, stereoisomer, tautomeric, conformational, or anomeric forms, including but not limited to, cis- and trans-forms; E- and Z-forms; c-, t-, and r-forms; endo- and exo-forms; R—, S—, and meso-forms; D- and L-forms; d- and l-forms; (+) and ( ⁇ ) forms; keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal- and anticlinal-forms; a- and ⁇ -forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and half chair-forms; and
- a compound described herein may be an enantiomerically enriched isomer of a stereoisomer described herein.
- the compound may have an enantiomeric excess of at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.
- Enantiomer when used herein, refers to either of a pair of chemical compounds whose molecular structures have a mirror-image relationship to each other.
- a preparation of a compound disclosed herein is enriched for an isomer of the compound having a selected stereochemistry, e.g., R or S, corresponding to a selected stereocenter.
- the compound has a purity corresponding to a compound having a selected stereochemistry of a selected stereocenter of at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.
- a composition described herein includes a preparation of a compound disclosed herein that is enriched for a structure or structures having a selected stereochemistry, e.g., R or S, at a selected stereocenter.
- a selected stereochemistry e.g., R or S
- Exemplary R/S configurations can be those provided in an example described herein.
- An “enriched preparation,” as used herein, is enriched for a selected stereoconfiguration of one, two, three or more selected stereocenters within the subject compound.
- Exemplary selected stereocenters and exemplary stereoconfigurations thereof can be selected from those provided herein, e.g., in an example described herein.
- enriched is meant at least 60%, e.g., of the molecules of compound in the preparation have a selected stereochemistry of a selected stereocenter. In an embodiment it is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.
- Enriched refers to the level of a subject molecule(s) and does not connote a process limitation unless specified.
- Compounds may be prepared in racemic form or as individual enantiomers or diastereomers by either stereospecific synthesis or by resolution.
- the compounds may, for example, be resolved into their component enantiomers or diastereomers by standard techniques, such as the formation of stereoisomeric pairs by salt formation with an optically active base, followed by fractional crystallization and regeneration of the free acid.
- the compounds may also be resolved by formation of stereoisomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.
- the enantiomers also may be obtained from kinetic resolution of the racemate of corresponding esters using lipase enzymes.
- isomers are structural (or constitutional) isomers (i.e., isomers which differ in the connections between atoms rather than merely by the position of atoms in space).
- a reference to a methoxy group, —OCH 3 is not to be construed as a reference to its structural isomer, a hydroxymethyl group, —CH 2 OH.
- a reference to ortho-chlorophenyl is not to be construed as a reference to its structural isomer, meta-chlorophenyl.
- a reference to a class of structures may well include structurally isomeric forms falling within that class (e.g., C 3 -alkyl or propyl includes n-propyl and iso-propyl; C 4 -alkyl or butyl includes n-, iso-, sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl).
- C 3 -alkyl or propyl includes n-propyl and iso-propyl
- C 4 -alkyl or butyl includes n-, iso-, sec-, and tert-butyl
- methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl
- keto-, enol-, and enolate-forms as in, for example, the following tautomeric pairs: keto/enol, imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, N-nitroso/hydroxyazo, and nitro/aci-nitro.
- H may be in any isotopic form, including 1 H, 2 H (D), and 3 H (T); C may be in any isotopic form, including 12C, 13 C, and 14 C; O may be in any isotopic form, including 16 O and 18 O; and the like.
- a compound described herein can be in the form of a salt, e.g., a pharmaceutically acceptable salt.
- pharmaceutically acceptable salt includes salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. Neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in a conventional manner.
- the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of this disclosure. Examples of pharmaceutically acceptable salts are discussed in Berge et al, 1977, “Pharmaceutically Acceptable Salts.” J. Pharm. Sci. Vol. 66, pp. 1-19.
- a salt may be formed with a suitable cation.
- suitable inorganic cations include, but are not limited to, alkali metal ions such as Na + and K + , alkaline earth cations such as Ca 2+ and Mg 2+ , and other cations.
- suitable organic cations include, but are not limited to, ammonium ion (i.e., NH 4 ) and substituted ammonium ions (e.g., NH 3 R 1 + , NH 2 R 2+ , NHR 3 + , NR 4 + ).
- substituted ammonium ions examples include those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine.
- a salt may be formed with a suitable anion.
- suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous.
- Suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetyoxybenzoic, acetic, ascorbic, aspartic, benzoic, camphorsulfonic, cinnamic, citric, edetic, ethanedisulfonic, ethanesulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, hydroxymaleic, hydroxynaphthalene carboxylic, isethionic, lactic, lactobionic, lauric, maleic, malic, methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic, pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic, stearic, succinic, sulfanilic, tartaric, toluenesulfonic, and valeric.
- a reference to a particular compound also includes salt forms thereof.
- chemically protected form is used herein in the conventional chemical sense and pertains to a compound in which one or more reactive functional groups are protected from undesirable chemical reactions under specified conditions (e.g., pH, temperature, radiation, solvent, and the like).
- specified conditions e.g., pH, temperature, radiation, solvent, and the like.
- well known chemical methods are employed to reversibly render unreactive a functional group, which otherwise would be reactive, under specified conditions.
- one or more reactive functional groups are in the form of a protected or protecting group (also known as a masked or masking group or a blocked or blocking group).
- a wide variety of such “protecting,” “blocking,” or “masking” methods are widely used and well known in organic synthesis.
- a compound which has two nonequivalent reactive functional groups both of which would be reactive under specified conditions, may be derivatized to render one of the functional groups “protected,” and therefore unreactive, under the specified conditions; so protected, the compound may be used as a reactant which has effectively only one reactive functional group.
- the protected group may be “deprotected” to return it to its original functionality.
- a hydroxy group may be protected as an ether (—OR) or an ester (—OC(O)R), for example, as: a t-butyl ether; a benzyl, benzhydryl(diphenylmethyl), or trityl(triphenylmethyl)ether; a trimethylsilyl or t-butyldimethylsilyl ether; or an acetyl ester (—OC(O)CH 3 , —OAc).
- an ether —OR
- an ester —OC(O)R
- An aldehyde or ketone group may be protected as an acetal (RCH(OR) 2 ) or ketal (R 2 C(OR) 2 ), respectively, in which the carbonyl group (R 2 C ⁇ O) is converted to a diether (R 2 C(OR) 2 ), by reaction with, for example, a primary alcohol.
- the aldehyde or ketone group is readily regenerated by hydrolysis using a large excess of water in the presence of acid.
- An amine group may be protected, for example, as an amide (—NRC(O)R) or a urethane (—NRC(O)OR), for example, as: a methyl amide (—NHC(O)CH 3 ); a benzyloxy amide (—NHC(O)OCH 2 C 6 H 5 , —NH-Cbz); as a t-butoxy amide (—NHC(O)OC(CH 3 ) 3 , —NH—Boc); a 2-biphenyl-2-propoxy amide (—NHCO(O)C(CH 3 ) 2 C 6 H 4 C 6 H 5 , —NH-Bpoc), as a 9-fluorenylmethoxy amide (—NH-Fmoc), as a 6-nitroveratryloxy amide (—NH-Nvoc), as a 2-trimethylsilylethyloxy amide (—NH-Teoc), as a 2,2,2-trichloroethyl
- a carboxylic acid group may be protected as an ester, for example, as: an alkyl ester (e.g., a methyl ester; a t-butyl ester); a haloalkyl ester (e.g., a haloalkyl ester); a trialkylsilylalkyl ester; or an arylalkyl ester (e.g., a benzyl ester; a nitrobenzyl ester); or as an amide, for example, as a methyl amide.
- an alkyl ester e.g., a methyl ester; a t-butyl ester
- a haloalkyl ester e.g., a haloalkyl ester
- a trialkylsilylalkyl ester e.g., a benzyl ester; a nitrobenzyl ester
- an amide for example, as a methyl
- a thiol group may be protected as a thioether (—SR), for example, as: a benzyl thioether; an acetamidomethyl ether (—S—CH 2 NHC(O)CH 3 )
- the present invention may also provide compounds that are in a prodrug form.
- Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds described herein.
- Prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
- a compound described herein can also be modified by appending appropriate functionalities to enhance selective biological properties.
- modifications are known in the art and include those that increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism, and/or alter rate of excretion. Examples of these modifications include, but are not limited to, esterification with polyethylene glycols, derivatization with pivolates or fatty acid substituents, conversion to carbamates, hydroxylation of aromatic rings, and heteroatom substitution in aromatic rings.
- the disclosure provides a composition
- a compound of formula (I) as described herein e.g., a compound of formula (I), a compound of formula (Ia), or a compound of formula (Ib)
- a prostaglandin or a prostaglandin analog e.g., a compound of formula (IV)
- the disclosure may provide a composition comprising 2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride (e.g., the racemic compound or the (R) or (S) enantiomer), and a compound selected from the group consisting of latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, latanoprostene bunod, unoprostone, PGF 2 ⁇ and fluprostenol.
- 2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride e.g., the racemic compound or the (R) or (S) enantiomer
- the disclosure may provide a composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate (e.g., the racemic compound or the (R) or (S) enantiomer), and a compound selected from the group consisting of latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, latanoprostene bunod, unoprostone, PGF 2 ⁇ and fluprostenol.
- the disclosure provides a composition comprising a compound of formula (II) as described herein.
- the disclosure provides a composition comprising a compound of formula (III) as described herein.
- compositions of the present disclosure may comprise safe and effective amounts of the subject compounds.
- safe and effective amount means an amount of a compound sufficient to significantly induce a positive modification in the condition to be treated, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment.
- a safe and effective amount of a compound will vary with the particular condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of treatment, the nature of concurrent therapy, the particular pharmaceutically-acceptable carrier utilized, and like factors within the knowledge and expertise of the attending physician.
- a composition may include a compound of formula (I), (Ia), (Ib), (II) or (III) at an amount of about 0.001% to about 2.0% w/v, e.g., about 0.01% to about 1.0% w/v.
- a compound of formula (I), (Ia), (Ib), (II) or (III) may be included in a composition at an amount of less than about 0.0025%, less than about 0.010%, less than about 0.015%, less than about 0.025%, less than about 0.05%, less than about 0.080%, less than about 0.10%, less than about 0.20%, less than about 0.40%, less than about 0.60%, less than about 0.80%, less than about 0.10%, less than about 0.5%, less than about 0.7%, less than about 1.0%, less than about 1.2%, less than about 1.4%, less than about 1.5%, less than about 1.6%, less than about 1.8, less than about 2.0%, at least about 0.0025%, at least about 0.010%, at least about 0.015%, at least about 0.020%, at least about 0.05%, at least about 0.075%, at least about 0.10%, at least about 0.20%, at least about 0.40%, at least about 0.60%, at least about 0.80, at least about
- a composition may include a prostaglandin or a prostaglandin analog (e.g., a compound of formula (IV), or latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, latanoprostene bunod, unoprostone, PGF 2 ⁇ or fluprostenol) at an amount of about 0.0001% to about 0.5% w/v, e.g., about 0.0005% to about 0.1% w/v, or about 0.001% to about 0.05%.
- a prostaglandin or a prostaglandin analog e.g., a compound of formula (IV), or latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, latanoprostene bunod, unoprostone, PGF 2 ⁇ or fluprostenol
- a prostaglandin or prostaglandin analog may be included in a composition at an amount of about 0.001%, about 0.002%, about 0.003%, about 0.004%, about 0.005%, about 0.006%, about 0.007%, about 0.008%, about 0.009%, about 0.010%, about 0.011%, about 0.012%, about 0.013%, about 0.014%, about 0.015%, about 0.016%, about 0.017%, about 0.018%, about 0.019%, about 0.020%, about 0.021%, about 0.022%, about 0.023%, about 0.024%, about 0.025%, about 0.026%, about 0.027%, about 0.028%, about 0.029%, about 0.030%, about 0.031%, about 0.032%, about 0.033%, about 0.034%, about 0.035%, about 0.036%, about 0.037%, about 0.038%, about 0.039%, about 0.040%, about 0.041%, about 0.042%, about 0.043%, about 0.044%, about 0.045%, about 0.04
- compositions of the present disclosure may further include one or more pharmaceutically acceptable excipients.
- compositions may include additional, pharmaceutically acceptable components such as buffers, tonicity agents, chelating agents, sugars or sugar alcohols, viscosity enhancers and surfactants.
- a buffer may comprise, for example, phosphate buffer, borate buffer, citrate buffer, maleate buffer, tartrate buffer, acetate buffer, tris(hydroxymethyl)aminomethane (TRIS), an amino acid buffer (e.g., glycine), combination buffers such as borate/phosphate buffer, citrate/phosphate buffer, and the like.
- a composition may include an amount of a buffer that is effective to provide a suitable buffering capacity to a composition.
- Other components of the compositions while having other functions, may also affect the buffer capacity. For example, ethylenediaminetetraacetic acid (EDTA), often used as a chelating agent, can have an effect on the buffer capacity of a solution.
- EDTA ethylenediaminetetraacetic acid
- Compositions may include one or more tonicity agents, such that the composition may be isotonic with body fluids.
- a tonicity agent can be non-ionic or ionic.
- Non-ionic tonicity agents include sugars, sugar alcohols and other polyols, diols such as glycerol, mannitol, erythritol, and sugars such as dextrose.
- Other non-ionic tonicity agents such as polyethylene glycols, propylene glycol, which also function as co-solvents, can also be used.
- a tonicity agent can also be an ionic agent such as, for example, sodium chloride, potassium chloride, a balanced salt solution, sodium phosphate, or sodium citrate.
- a non-ionic tonicity agent may be included in a composition at an amount of about 0.10 to about 20%, about 1.0 to about 10%, or about 2.0 to about 6.0%.
- An ionic tonicity agent may be included in a composition at an amount of about 0.10% to about 2.5%, about 0.25% to about 2.0%, or about 0.50% to about 1.0% w/v.
- Compositions may also include one or more chelating agents or sequestering agents.
- chelating agents A wide range of organic acids, amines or compounds which include an acid group and an amine function are capable of acting as chelating agents.
- Ethylenediaminetetraacetic acid and its alkali metal salts, are suitable chelating agents, such as the disodium salt of EDTA (also known as disodium edetate).
- a chelating agent may be included in a composition at an amount of about 0.001% to about 0.25% w/v, about 0.005% to about 0.15% w/v, or about 0.01% to about 0.1% w/v.
- a composition may include a chelating agent in an amount effective to enhance the effectiveness of an antimicrobial component and/or to complex with metal ions.
- Compositions may further include one or more preservatives.
- Suitable preservatives include, but are not limited to, sodium bisulfite, sodium bisulfate, sodium thiosulfate, ascorbate, benzalkonium chloride, benzododecinium bromide, chlorobutanol, thimerosal, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, parabens such as methylparaben, ethylparaben and propylparaben, polyvinyl alcohol, benzyl alcohol, phenylethanol, sodium benzoate, sorbic acid, polyquaternium-1, and the like and mixtures thereof.
- a composition may include a preservative in amounts of 0.001 to about 1% or about 0.005 to about 0.10% w/v. In embodiments, a composition may include a preservative in an amount that is effective to inhibit microbial growth or contamination of the composition.
- Compositions may additionally include a surfactant.
- Surfactants include non-ionic, anionic, amphoteric and zwitterionic surfactants.
- Exemplary surfactants include but are not limited to sodium lauryl sulfate, polyethoxylated sorbitan fatty acid esters, polyoxyethylene alkyl ethers, polyoxyethylene stearates (e.g., polyoxyethylene(40) stearate such as MyrjTM-52), poloxamers, polaxamines, sorbitan fatty acid esters, polyethylene glycols (e.g., PEG-400), polyethoxylated alcohols, polyethoxylated castor oils (e.g., PEG-40 hydrogenated castor oil, such as Cremophor® RH 40), docusate sodium, quaternary ammonium compounds, medium and long chain fatty acids, sugar esters of fatty acids and glycerides of fatty acids, lecithin, polysorbate 80
- Suitable surfactants include those disclosed in the C.T.F.A. Cosmetic Ingredient Handbook, 1992, pp. 587-592; Remington's Pharmaceutical Sciences, 15th Ed. 1975, pp. 335-337; and McCutcheon's Volume 1, Emulsifiers & Detergents, 1994, North American Edition, pp. 236-239. Surfactants may be included in compositions at amounts of about 0.01% to about 5%, or about 0.1% to about 2% w/v.
- compositions may also include a viscosity enhancer, which may increase the resident time of a composition on the ocular surface.
- exemplary viscosity enhancers include but are not limited to water soluble natural gums, cellulose-derived polymers and the like. Suitable natural gums include guar gum, gum tragacanth and the like. Suitable cellulose-derived viscosity inducing components include cellulose-derived polymers, such as sodium carboxymethylcellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose and the like. Viscosity enhancers may be included in compositions at amounts of about 0.01% to about 5%, or about 0.1% to about 3% w/v.
- compositions described herein may also include a solvent.
- Compositions are typically aqueous, but may also include optional co-solvents.
- Suitable co-solvents include but are not limited to alcohols such as ethanol and isopropanol, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethylsulfoxide, dimethyl formamide, castor oil and combinations thereof.
- the balance of a composition may comprise solvent.
- compositions can affect both stability of the compound and efficacy. For example, higher pH may result in decomposition of a compound of formula (I), while lower pH may be irritating to the eye.
- the pH may be about 4.0 to about 7.0, or about 5.0 to about 6.0.
- a composition may have a pH of at least about 5.0, at least about 5.5, at least about 6.0, at least about 6.5, at least about 7.0, less than about 5.0, less than about 5.5, less than about 6.0, less than about 6.5, less than about 7.0, about 5.0, about 5.1, about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, or about 6.0.
- Composition pH can be adjusted with acid or base, if necessary. Any acid or base compatible with the components of the composition can be used.
- Exemplary acids include hydrochloric acid, citric acid, gluconic acid, lactic acid, acetic acid, and glycolic acid.
- Exemplary bases include sodium hydroxide, potassium hydroxide, and triethanolamine.
- compositions may be prepared using standard methods.
- composition components may be combined in water (e.g., purified water) with stirring, followed by pH adjustment to a suitable final pH.
- Techniques for preparing compositions may generally be found in “Remington's Pharmaceutical Sciences”, (Meade Publishing Co., Easton, Pa.).
- compositions When preparing compositions, components should be selected to optimize solubility, stability and compatibility. Compositions should typically be sterile and stable under the conditions of manufacture and storage. Compositions may be sterilized by filtering the composition through a sterilizing grade filter, such as a filter with a 0.22 micron nominal pore size.
- a sterilizing grade filter such as a filter with a 0.22 micron nominal pore size.
- compositions may be evaluated for stability using established procedures. For example, compositions may be subjected to accelerated stability testing. For example, compositions remain stable, and do not undergo precipitation or become cloudy when they are stored at 40° C. for at least 1 month, 3 months or 6 months prior to evaluation.
- the active component e.g., a 6- or 7-aminoisoquinoline compound
- Methods of evaluating such compounds include, for example, high performance liquid chromatography (HPLC) or determination of optical rotation (e.g., to determine if a compound has racemized).
- Compositions may also be evaluated using the Preservative Effectiveness Test of the United States Pharmacopoeia for parenteral/ophthalmic products.
- the Preservative Effectiveness Test of the United States Pharmacopoeia for parenteral/ophthalmic products.
- five indicator organisms are utilized for the purpose of challenging the preservative system in a product.
- Three of the five USP indicator organisms address the growth of bacteria: Escherichia coli, Pseudomonas aeruginosa , and Staphylococcus aureus.
- Candida albicans is the representative yeast, while Aspergillus niger is a mold.
- a product is inoculated (contaminated) with a number of organisms between 1 ⁇ 10 5 (100,000) to 1 ⁇ 10 6 (1,000,000) colony forming units (CFU) per mL of product.
- CFU colony forming units
- the composition is tested to determine its ability to control reproduction or destroy the microorganisms. A logarithmic reduction is evaluated at each test interval required for the category. By test definition, any growth over the allotted amount for any of the indicated microorganisms renders the preservative in the product not effective.
- Compositions may also be evaluated using the European Pharmacopoeia Preservative Effectiveness Test, which also evaluates growth of P. aeruginosa, S. aureus, C. albicans and A. niger .
- the compositions of the present disclosure will pass at least one of these preservative effectiveness tests.
- Pharmacological activity for glaucoma can be demonstrated using assays designed to test the ability of the subject compounds to decrease intraocular pressure. Examples of such assays are described in the following paper, incorporated herein by reference: C. Liljebris, G. Selen, B. Resul, J. Stemschantz, and U.hacksell, “Derivatives of 17-Phenyl-18,19,20-trinorprostaglandin F 2 ⁇ Isopropyl Ester: Potential Anti-glaucoma Agents”, Journal of Medicinal Chemistry, Vol. 38 (2) 1995, pp. 289-304. Further methods are described in the Examples.
- One aspect of the disclosure relates to a method of treating an ocular disorder in a subject in need of treatment, comprising administering to the subject a safe and effective amount of a composition comprising an isoquinoline compound such as a compound of formula (I), and a prostaglandin or a prostaglandin analog.
- Another embodiment includes a method of treating an ocular disorder in a subject in need of treatment, comprising administering to the subject a safe and effective amount of a composition comprising a compound of formula (II).
- Another embodiment of the disclosure includes a method of reducing intraocular pressure comprising administering to a subject in need thereof a safe and effective amount of a composition comprising an isoquinoline compound such as a compound of formula (I), and a prostaglandin or a prostaglandin analog.
- Another embodiment includes a method of reducing intraocular pressure comprising administering to a subject in need thereof a safe and effective amount of a composition comprising a compound of formula (II).
- the compounds of formula (I) and (II) and compositions including them may have kinase inhibitory activity and are thus useful in influencing or inhibiting the action of kinases, and in treatment and/or prevention of diseases or conditions influenced by kinases.
- exemplary kinases that may be influenced include, but are not limited to, ROCK-I, ROCK-II, PKA, PKC, CAM Kinases, GRK-2, GRK-3, GRK-5 or GRK-6.
- the kinase inhibited is a Rho-associated protein kinase.
- compositions of the present disclosure may be topically administered.
- Topical compositions that can be applied locally to the eye may be in any form known in the art, non-limiting examples of which include drops, sprays, ointments, or a sustained or non-sustained release unit placed in the conjunctival cul-du-sac of the eye or another appropriate location.
- Dosages may be varied based on the patient being treated, the condition being treated, the severity of the condition being treated, the route of administration, etc. to achieve the desired effect.
- Administration of a compound or a composition described herein may result in a decrease in intraocular pressure (IOP) of at least about 3.0 mmHg, at least about 3.5 mmHg, at least about 4.0 mmHg, at least about 4.5 mmHg, at least about 5.0 mmHg, at least about 5.5 mmHg, at least about 6.0 mmHg, at least about 6.5 mmHg, at least about 7.0 mmHg, at least about 7.5 mmHg, at least about 8.0 mmHg, at least about 8.5 mmHg, at least about 9.0 mmHg, at least about 9.5 mmHg, at least about 10.0 mmHg, about 3.0 mmHg, about 3.5 mmHg, about 4.0 mmHg, about 4.5 mmHg, about 5.0 mmHg, about 5.5 mmHg, about 6.0 mmHg, about 6.5 mmHg, about 7.0 mmHg, about 7.5
- administration of a composition comprising a compound of formula (I) and a prostaglandin or prostaglandin analog may reduce intraocular pressure more than either single compound alone, or more than intraocular pressure is reduced when both compounds are administered to a subject in separate compositions.
- Topical pharmaceutical compositions for lowering intraocular pressure were prepared by conventional methods and formulated as follows:
- Formulation 1 2 3 4 (% w/w) (% w/w) (% w/w) (% w/w) (% w/w) (rac)-2-(dimethylamino)- 0.5 0.5 0.25 0.5 N-(1-hydroxyisoquinolin- 6-yl)-2-(thiophen-3- yl)acetamide hydrochloride Travoprost 0.004 0.004 0.004 0.004 Boric acid 0.05 0.05 0.05 0.05 0.05 0.05 0.05 D-mannitol 3.0 3.0 3.0 3.0 Benzalkonium chloride 0.015 0.015 0.015 — Polyoxyl 40 stearate 0.5 — 0.5 0.5 (Myrj-52) Cremophor RH 40 — 0.5 — — Polyethylene glycol 400 2.5 2.5 2.5 2.5 2.5 (PEG-400) EDTA 0.01 0.01 0.01 0.01 0.01 Purified water q.s. q.s. q.s. q.s.
- Formulations 1-3 were prepared by adding boric acid, D-mannitol, PEG-400, EDTA, and Myrj-52 or Cremophor RH40 in a labeled 150-milliliter (mL) plastic container. 100 milliliters (mL) of purified water were then added to bring the solution almost to 100%. The solution was stirred for 10 minutes. Stock solutions of 1.5% benzalkonium chloride, 0.4% travoprost, and (rac)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride were then added and dissolved by stirring the solution for another 10 minutes, and the pH was adjusted to approximately 5.5.
- Formulation 4 was prepared by adding boric acid, D-mannitol, PEG-400, EDTA, and Myrj-52 or Cremophor RH40 in a labeled 150-mL plastic container. 100 mL purified water was then added to bring the solution almost to 100%. The solution was stirred for 10 minutes. (R)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride and travoprost were then added and dissolved by stirring the solution for another 10 minutes, and the pH was adjusted to approximately 5.5.
- Formulation 1 passed the requirements of the United States Pharmacopoeia Preservative Effectiveness Test for parenteral/ophthalmic products (USP), the European Pharmacopoeia Preservative Effectiveness Test (EP-A) and the European Pharmacopoeia Preservative Effectiveness Test (EP-B).
- USP United States Pharmacopoeia Preservative Effectiveness Test for parenteral/ophthalmic products
- EP-A European Pharmacopoeia Preservative Effectiveness Test
- EP-B European Pharmacopoeia Preservative Effectiveness Test
- Topical pharmaceutical compositions for lowering intraocular pressure were prepared by conventional methods and formulated as follows:
- Formulation 5 6 (% w/w) (% w/w) (rac)-2-(dimethylamino)-N-(1- 0.5 0.7 hydroxyisoquinolin-6-yl)-2-(thiophen-3- yl)acetamide hydrochloride Latanoprost 0.005 0.005 Sodium Phosphate Monobasic 0.031 0.0155 Sodium Phosphate Dibasic 0.07 0.0035 Benzalkonium chloride 0.015 0.015 sodium chloride 0.7 0.7 EDTA 0.05 0.05 Purified water q.s. q.s.
- Formulations 5 and 6 were prepared by adding sodium phosphate monobasic, sodium phosphate dibasic, sodium chloride, and EDTA in a labeled 150-milliliter (mL) plastic storage container. 100 milliliter (mL) of purified water was then added to bring the solution almost to 100%. The solution was stirred for 10 minutes. Stock solutions of 1.5% benzalkonium chloride, and 0.5% latanoprost, and (rac)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride were then added and dissolved by stirring the solution for another 10 minutes, and the pH was adjusted to approximately 5.5.
- Formulation 7 (% w/w) (% w/w) (rac)-2-(dimethylamino)-N-(1- 0.5 0.7 hydroxyisoquinolin-6-yl)-2-(thiophen-3- yl)acetamide hydrochloride Latanoprost 0.005 0.005 Boric acid 0.05 0.05 D-mannitol 4.3 4.0 Benzalkonium chloride 0.015 0.015 EDTA 0.01 0.01 Purified water q.s. q.s.
- Formulations 7 and 8 were prepared by adding boric acid, D-mannitol, and EDTA in a labeled 150-milliliter (mL) plastic container. 100 milliliter (mL) of purified water was then added to bring the solution almost to 100%. The solution was stirred for 10 minutes. Stock solutions of 1.5% benzalkonium chloride, 0.5% travoprost, and (rac)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride were then added and dissolved by stirring the solution for another 10 minutes, and the pH was adjusted to approximately 5.5.
- Topical pharmaceutical compositions for lowering intraocular pressure were prepared by conventional methods and formulated as follows:
- Formulation 9 10 11 (% w/w) (% w/w) (% w/w) (rac)-2-(dimethylamino)-N-(1- 0.5 0.5 0.5 hydroxyisoquinolin-6-yl)-2- (thiophen-3-yl)acetamide hydrochloride Bimatoprost 0.03 0.01 0.03 Boric acid — — 0.05 D-mannitol — — 4.3 Sodium Phosphate Monobasic 0.31 0.31 — Sodium Phosphate Dibasic 0.07 0.07 — Benzalkonium chloride 0.0075 0.02 — Sodium chloride 0.7 0.7 — EDTA 0.05 — Purified water q.s. q.s. q.s.
- Formulations 9 and 10 were prepared by adding sodium phosphate monobasic, sodium phosphate dibasic, sodium chloride, and EDTA in a labeled 150-milliliter (mL) plastic storage container. 100 milliliter (mL) of purified water was then added to bring the solution almost to 100%. The solution was stirred for 10 minutes. 1.5% stock solution of benzalkonium chloride, bimatoprost, and (rac)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride were then added and dissolved by stirring the solution for another 10 minutes, and the pH was adjusted to approximately 5.5.
- Formulation 11 was prepared by adding boric acid and D-mannitol in a labeled 150-milliliter (mL) plastic storage container. 100 milliliter (mL) of purified water was then added to bring the solution almost to 100%. The solution was stirred for 10 minutes. Bimatoprost and (rac)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride were then added and dissolved by stirring the solution for another 10 minutes, and the pH was adjusted to approximately 5.5.
- Formosan Rock monkeys Macaca cyclopis
- animal identification consisting of uniquely numbered tattoos and color-coded cage cards were used in this study.
- the animals were at least four years old, and weighed at least 4 kg.
- IOP intraocular pressure
- Rho Kinase inhibitor Three Rho Kinase inhibitor (ROCKi) formulations were prepared by dissolving 0.5% ROCKi (rac)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride directly in the commercially-used formulations of 0.004% travoprost (Travatan® Z), 0.005% latanoprost (Xalatan) and 0.01% bimatoprost (Lumigan), with adjustment of the final pH to 5.5.
- 0.004% travoprost Travatan® Z
- Xalatan latanoprost
- bimatoprost Limatoprost
- Topical pharmaceutical compositions for lowering intraocular pressure were prepared by conventional methods and formulated as follows:
- Formulation 12 13 (S)-4-(3-amino-1-(isoquinolin-6-ylamino)- 0.02 0.02 1-oxopropan-2-yl)benzyl 2,4- dimethylbenzoate Travoprost — 0.004 Boric acid 0.05 0.05 D-mannitol 4.7 3.5 Benzalkonium chloride 0.015 0.015 Polyoxyl 40 stearate (Myrj-52) — 0.5 Polyethylene glycol 400 (PEG-400) — 2.5 EDTA — 0.01 Purified water q.s. q.s.
- Formulation 12 was prepared by adding boric acid, D-mannitol, and EDTA in a labeled 150-mL plastic container. 100 mL purified water was then added to bring the solution almost to 100%. The solution was stirred for 10 minutes. Stock solution of 5% benzalkonium chloride and (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate were then added and dissolved by stirring the solution for another 10 minutes, and the pH was adjusted to approximately 5.0.
- Formulation 13 was prepared by adding boric acid, D-mannitol, PEG-400, EDTA, and Myrj-52 in a labeled 150-mL plastic container. 100 mL purified water was then added to bring the solution almost to 100%. The solution was stirred for 10 minutes. Stock solutions of 1.5% benzalkonium chloride, 0.4% travoprost, and ROCKi (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate were then added and dissolved by stirring the solution for another 10 minutes, and the pH was adjusted to approximately 5.0.
- a sterile, isotonic, aqueous solution was prepared, containing (rac)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride and travoprost at concentrations of 0.5% and 0.004%, respectively, and the following excipients: Boric Acid (NF), Mannitol (USP), Polyethylene glycol 400 (USP), Polyoxyl 40 Stearate (NF), Edetate Disodium (USP), Water for Injection (USP), and benzalkonium chloride (NF) 0.015% as a preservative.
- the product may be adjusted with NaOH (USP) and/or HCL (USP) to pH 5.2-5.9.
- IOP intraocular pressure
- Salts 24 and 25 were prepared similarly to salt 23.
- Salt 27 was prepared from 26 following the same method, but without heat.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/213,940 US20140275160A1 (en) | 2013-03-15 | 2014-03-14 | Combination therapy |
US15/142,461 US9849122B2 (en) | 2013-03-15 | 2016-04-29 | Combination therapy |
US15/627,238 US9993470B2 (en) | 2013-03-15 | 2017-06-19 | Combination therapy |
US15/970,635 US10588901B2 (en) | 2013-03-15 | 2018-05-03 | Combination therapy |
US16/780,294 US20200276179A1 (en) | 2013-03-15 | 2020-02-03 | Combination Therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361787883P | 2013-03-15 | 2013-03-15 | |
US14/213,940 US20140275160A1 (en) | 2013-03-15 | 2014-03-14 | Combination therapy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/142,461 Continuation US9849122B2 (en) | 2013-03-15 | 2016-04-29 | Combination therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140275160A1 true US20140275160A1 (en) | 2014-09-18 |
Family
ID=50588903
Family Applications (12)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/213,961 Active US9415043B2 (en) | 2013-03-15 | 2014-03-14 | Combination therapy |
US14/213,940 Abandoned US20140275160A1 (en) | 2013-03-15 | 2014-03-14 | Combination therapy |
US15/142,461 Active US9849122B2 (en) | 2013-03-15 | 2016-04-29 | Combination therapy |
US15/236,625 Active US9931336B2 (en) | 2013-03-15 | 2016-08-15 | Combination therapy |
US15/627,238 Active US9993470B2 (en) | 2013-03-15 | 2017-06-19 | Combination therapy |
US15/901,361 Active US10568878B2 (en) | 2013-03-15 | 2018-02-21 | Combination therapy |
US15/970,635 Active US10588901B2 (en) | 2013-03-15 | 2018-05-03 | Combination therapy |
US16/730,015 Active US11020385B2 (en) | 2013-03-15 | 2019-12-30 | Combination therapy |
US16/780,294 Abandoned US20200276179A1 (en) | 2013-03-15 | 2020-02-03 | Combination Therapy |
US17/238,550 Active US11185538B2 (en) | 2013-03-15 | 2021-04-23 | Compositions for treating glaucoma or reducing intraocular pressure |
US17/238,554 Active US11197853B2 (en) | 2013-03-15 | 2021-04-23 | Combination therapy |
US17/544,648 Abandoned US20220088000A1 (en) | 2013-03-15 | 2021-12-07 | Combination therapy |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/213,961 Active US9415043B2 (en) | 2013-03-15 | 2014-03-14 | Combination therapy |
Family Applications After (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/142,461 Active US9849122B2 (en) | 2013-03-15 | 2016-04-29 | Combination therapy |
US15/236,625 Active US9931336B2 (en) | 2013-03-15 | 2016-08-15 | Combination therapy |
US15/627,238 Active US9993470B2 (en) | 2013-03-15 | 2017-06-19 | Combination therapy |
US15/901,361 Active US10568878B2 (en) | 2013-03-15 | 2018-02-21 | Combination therapy |
US15/970,635 Active US10588901B2 (en) | 2013-03-15 | 2018-05-03 | Combination therapy |
US16/730,015 Active US11020385B2 (en) | 2013-03-15 | 2019-12-30 | Combination therapy |
US16/780,294 Abandoned US20200276179A1 (en) | 2013-03-15 | 2020-02-03 | Combination Therapy |
US17/238,550 Active US11185538B2 (en) | 2013-03-15 | 2021-04-23 | Compositions for treating glaucoma or reducing intraocular pressure |
US17/238,554 Active US11197853B2 (en) | 2013-03-15 | 2021-04-23 | Combination therapy |
US17/544,648 Abandoned US20220088000A1 (en) | 2013-03-15 | 2021-12-07 | Combination therapy |
Country Status (14)
Country | Link |
---|---|
US (12) | US9415043B2 (fr) |
EP (5) | EP4218759A3 (fr) |
JP (6) | JP2016515520A (fr) |
CN (3) | CN109528721B (fr) |
AU (4) | AU2014228790B2 (fr) |
CA (1) | CA2905089C (fr) |
DK (1) | DK3811943T3 (fr) |
ES (3) | ES2776199T3 (fr) |
FI (1) | FI3811943T3 (fr) |
HU (1) | HUE061618T2 (fr) |
NL (1) | NL301101I2 (fr) |
PL (1) | PL3811943T3 (fr) |
PT (1) | PT3811943T (fr) |
WO (1) | WO2014144781A1 (fr) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016029191A2 (fr) | 2014-08-22 | 2016-02-25 | Auckland Uniservices Limited | Modulateurs de canaux |
US9415043B2 (en) | 2013-03-15 | 2016-08-16 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US9512101B2 (en) | 2008-07-25 | 2016-12-06 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
WO2017086941A1 (fr) * | 2015-11-17 | 2017-05-26 | Aerie Pharmaceuticals, Inc. | Procédé de préparation d'inhibiteurs de kinase et de leurs intermédiaires |
US9890123B2 (en) | 2007-01-10 | 2018-02-13 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US9951059B2 (en) | 2009-05-01 | 2018-04-24 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US10624882B2 (en) | 2006-09-20 | 2020-04-21 | Aerie Pharmaceuticals, Inc. | Rho kinase inhibitors |
US10858339B2 (en) | 2017-03-31 | 2020-12-08 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US11389441B2 (en) | 2016-08-31 | 2022-07-19 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
US11427563B2 (en) | 2018-09-14 | 2022-08-30 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019529359A (ja) * | 2016-08-19 | 2019-10-17 | アエリエ ファーマシューティカルズ インコーポレイテッド | ベータ−アミノ−イソキノリニルアミド化合物 |
CN106620678A (zh) * | 2016-11-28 | 2017-05-10 | 同济大学 | Pka抑制剂h‑89的新应用 |
TWI800498B (zh) * | 2016-12-21 | 2023-05-01 | 義大利商吉斯藥品公司 | 作為Rho-激酶抑制劑之雙環二氫嘧啶-羧醯胺衍生物 |
US10442770B2 (en) | 2017-02-02 | 2019-10-15 | Assia Chemical Industries Ltd. | Solid state forms of netarsudil mesylate |
JP7108597B2 (ja) * | 2017-02-28 | 2022-07-28 | 興和株式会社 | 医薬品 |
WO2018159700A1 (fr) | 2017-02-28 | 2018-09-07 | 興和株式会社 | Préparation pharmaceutique |
CN110366416A (zh) | 2017-02-28 | 2019-10-22 | 兴和株式会社 | 医药 |
KR20230125086A (ko) | 2017-03-27 | 2023-08-28 | 코와 가부시키가이샤 | 의약 제제 |
KR102069205B1 (ko) * | 2017-08-09 | 2020-01-22 | 연성정밀화학(주) | 라타노프로스틴 부노드의 제조 방법 및 그를 위한 중간체 |
JP7165185B2 (ja) | 2018-02-28 | 2022-11-02 | 興和株式会社 | 医薬品製剤 |
CA3095730A1 (fr) * | 2018-03-30 | 2019-10-03 | Aerie Pharmaceuticals, Inc. | Sels de mono-(acide) de 6-aminoisoquinolines et leurs utilisations |
JP7191541B2 (ja) * | 2018-04-26 | 2022-12-19 | 興和株式会社 | 医薬製剤 |
CN112638386A (zh) * | 2018-08-31 | 2021-04-09 | 爱瑞制药公司 | 异喹啉-类固醇缀合物及其用途 |
CN110437043A (zh) * | 2019-08-24 | 2019-11-12 | 黄泳华 | 由白藜芦醇与前列腺素类似物剂构成的共晶及其在制备抗肿瘤药物中的用途 |
US20210212998A1 (en) * | 2020-01-08 | 2021-07-15 | Aerpio Pharmaceuticals, Inc. | Combinations of Tie-2 Activators and Prostaglandins and Uses Thereof |
EP4146664A2 (fr) | 2020-05-01 | 2023-03-15 | Ripple Therapeutics Corporation | Compositions hétérodimères et méthodes pour le traitement de troubles oculaires |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090186917A1 (en) * | 2008-01-17 | 2009-07-23 | Aerie Pharmaceuticals, Inc. | 6-And 7-amino isoquinoline compounds and methods for making and using the same |
US20100280011A1 (en) * | 2009-05-01 | 2010-11-04 | Delong Mitchell A | Dual mechanism inhibitors for the treatment of disease |
Family Cites Families (156)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT251624B (de) | 1962-05-02 | 1967-01-10 | Knapsack Ag | Ferrosilizium als Desoxydations-, Schlackenreduktions-, Impf- und/oder Legierungsmittel |
DE2623228C3 (de) | 1976-05-24 | 1981-09-10 | Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren | N-Acyl-substituierte Benzamide, Verfahren zu ihrer Herstellung und Arzneimittel, enthaltend solche Benzamide |
JPS5587771A (en) | 1978-12-27 | 1980-07-02 | Teikoku Hormone Mfg Co Ltd | 1-phenylisoquinoline derivative |
US4456757A (en) | 1981-03-20 | 1984-06-26 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinolinesulfonyl derivatives and process for the preparation thereof |
JPS5993054A (ja) | 1982-11-18 | 1984-05-29 | Asahi Chem Ind Co Ltd | イソキノリンスルホン酸アミド誘導体 |
DK8386A (da) | 1986-01-15 | 1987-07-09 | Tpo Pharmachim | Nye n-substituerede 1-benzyl-2-carbamoyltetrahydroisoquinoliner og fremgangsmaade til fremstilling af samme |
US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
US5591887A (en) | 1987-04-30 | 1997-01-07 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
JPH01139528A (ja) | 1987-11-24 | 1989-06-01 | Showa Denko Kk | 抗潰瘍剤 |
DE1300150T1 (de) | 1988-09-06 | 2003-09-18 | Pharmacia Ab | Prostaglandin-Derivate zur Behandlung von Glaukom oder Augenüberdruck |
ES2075082T3 (es) | 1989-03-28 | 1995-10-01 | Nisshin Flour Milling Co | Derivados de isoquinolina para el tratamiento del glaucoma o hipertension ocular. |
KR920008026A (ko) | 1990-10-24 | 1992-05-27 | 오노 화아마슈티칼 캄파니 리미팃드 | 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물 |
WO1993018028A1 (fr) | 1992-03-12 | 1993-09-16 | Smithkline Beecham Plc | Derives d'indole utilises comme antagonistes de 5ht¿1c? |
US5972991A (en) | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
DE4332168A1 (de) | 1993-02-22 | 1995-03-23 | Thomae Gmbh Dr K | Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US5510383A (en) | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
US6124344A (en) | 1993-12-28 | 2000-09-26 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US5462968A (en) | 1994-01-19 | 1995-10-31 | Allergan, Inc. | EP2 -receptor agonists as agents for lowering intraocular pressure |
US5698733A (en) | 1994-09-30 | 1997-12-16 | Alcon Laboratories, Inc. | Use of 9-deoxy prostaglandin derivatives to treat glaucoma |
WO1998021180A1 (fr) | 1995-06-07 | 1998-05-22 | Alcon Laboratories, Inc. | Prostaglandines aryle ou heteroaryle a conformation rigide utilisees dans le traitement des glaucomes |
US5814660A (en) | 1995-12-22 | 1998-09-29 | Alcon Laboratories, Inc. | 9-oxa prostaglandin analogs as ocular hypotensives |
ES2225897T3 (es) | 1995-12-22 | 2005-03-16 | Alcon Laboratories, Inc. | Analogos de tetrahidrofurano sustituido de prostaglandinas como hipotensores oculares. |
US5866602A (en) | 1995-12-22 | 1999-02-02 | Alcon Laboratories, Inc. | Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives |
US5798380A (en) | 1996-02-21 | 1998-08-25 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
US6586425B2 (en) | 1996-02-21 | 2003-07-01 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
DE69714274T3 (de) | 1996-09-17 | 2006-06-01 | Asahi Glass Co., Ltd. | Fluorierte prostaglandinderivate und medikamente |
EP0944593A2 (fr) | 1996-11-12 | 1999-09-29 | Alcon Laboratories, Inc. | ANALOGUES $i(CIS)-$g(D)?4 DE PROSTAGLANDINES SERVANT D'HYPOTENSEURS OCULAIRES |
WO1998020880A2 (fr) | 1996-11-12 | 1998-05-22 | Alcon Laboratories, Inc. | 11-halo prostaglandines destinees au traitement du glaucome ou de l'hypertension oculaire |
AU5355498A (en) | 1996-11-12 | 1998-06-03 | Alcon Laboratories, Inc. | 15-fluoro prostaglandins as ocular hypotensives |
AU5258698A (en) | 1996-11-12 | 1998-06-03 | Alcon Laboratories, Inc. | 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension |
EP0968183A2 (fr) | 1997-03-07 | 2000-01-05 | Alcon Laboratories, Inc. | 13-thia prostaglandines destinees a etre utilisees dans la therapie du glaucome |
WO1998050024A1 (fr) | 1997-05-09 | 1998-11-12 | The Mount Sinai School Of Medicine Of The City University Of New York | Traitement du glaucome a base de 8-iso-prostaglandines |
US5891646A (en) | 1997-06-05 | 1999-04-06 | Duke University | Methods of assaying receptor activity and constructs useful in such methods |
SE9702706D0 (sv) | 1997-07-11 | 1997-07-11 | Pharmacia & Upjohn Ab | Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma |
KR20010023839A (ko) | 1997-09-09 | 2001-03-26 | 데이비드 엠 모이어 | Fp 작동약으로 유용한 방향족 c16-c20-치환된테트라히드로 프로스타글란딘 |
EP1021402B1 (fr) | 1997-09-09 | 2005-11-23 | Duke University | Prostaglandines aromatiques tetrahydro substituees par c16-c20 utilisees comme agonistes fp |
US6048895A (en) | 1997-09-09 | 2000-04-11 | The Procter & Gamble Company | Aromatic C16-C20 substituted tetrahydro prostaglandins useful as FP agonists |
US5877211A (en) | 1997-11-21 | 1999-03-02 | Allergan | EP2 receptor agonists as neuroprotective agents for the eye |
WO1999032441A1 (fr) | 1997-12-22 | 1999-07-01 | Alcon Laboratories, Inc. | 13-oxa prostaglandines pour le traitement du glaucome et de l'hypertension oculaire |
CN1146423C (zh) | 1998-07-14 | 2004-04-21 | 阿尔康实验室公司 | 前列腺素产品 |
TWI249520B (en) | 1998-07-15 | 2006-02-21 | Ono Pharmaceutical Co | 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient |
US6720175B1 (en) | 1998-08-18 | 2004-04-13 | The Johns Hopkins University School Of Medicine | Nucleic acid molecule encoding homer 1B protein |
US20020065296A1 (en) | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
AU5723500A (en) | 1999-05-24 | 2000-12-12 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
EP1192135A2 (fr) | 1999-06-14 | 2002-04-03 | Eli Lilly And Company | Composes |
ES2311479T3 (es) | 1999-11-26 | 2009-02-16 | SHIONOGI & CO., LTD. | Antagonistas de npy-y5. |
CN1217936C (zh) | 1999-12-28 | 2005-09-07 | 卫材株式会社 | 含有磺酰胺的杂环化合物 |
YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
NZ520299A (en) | 2000-02-03 | 2004-05-28 | Eisai Co Ltd | Integrin expression inhibitors containing sulphonamide derivatives |
US6410566B1 (en) | 2000-05-16 | 2002-06-25 | Teijin Limited | Cyclic amine derivatives and their use as drugs |
US7087632B2 (en) | 2001-03-05 | 2006-08-08 | Transtech Pharma, Inc. | Benzimidazole derivatives as therapeutic agents |
US6908741B1 (en) | 2000-05-30 | 2005-06-21 | Transtech Pharma, Inc. | Methods to identify compounds that modulate RAGE |
US6855690B2 (en) * | 2000-06-01 | 2005-02-15 | Children's Medical Center Corporation | Methods and compositions for treating ocular disorders |
US6323228B1 (en) | 2000-09-15 | 2001-11-27 | Abbott Laboratories | 3-substituted indole angiogenesis inhibitors |
AU1401902A (en) | 2000-10-17 | 2002-04-29 | Applied Research Systems | Pharmaceutically active sulfanilide derivatives |
US7163800B2 (en) | 2000-11-03 | 2007-01-16 | Molecular Devices Corporation | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity |
WO2002085857A2 (fr) | 2001-04-20 | 2002-10-31 | Bayer Corporation | Inhibition de la kinase raf a l'aide d'urees de quinolyl, d'isoquinolyl ou de pyridyl |
US6956035B2 (en) | 2001-08-31 | 2005-10-18 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
WO2003059913A1 (fr) | 2002-01-10 | 2003-07-24 | Bayer Healthcare Ag | Inhibiteurs de la rho-kinase |
TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
AU2003245773A1 (en) | 2002-02-15 | 2003-09-04 | Glaxo Group Limited | Vanilloid receptor modulators |
US20040180889A1 (en) | 2002-03-01 | 2004-09-16 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
CN101613321A (zh) | 2002-03-05 | 2009-12-30 | 特兰斯泰克制药公司 | 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物 |
US7645878B2 (en) | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
GB0206876D0 (en) | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
ATE420109T1 (de) | 2002-05-13 | 2009-01-15 | Molecular Devices Corp | Konstitutiv translozierende zelllinie |
JP4482726B2 (ja) * | 2002-08-29 | 2010-06-16 | 参天製薬株式会社 | Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤 |
TWI337881B (en) | 2002-08-29 | 2011-03-01 | Santen Pharmaceutical Co Ltd | Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin |
WO2004022753A1 (fr) | 2002-08-30 | 2004-03-18 | Anges Mg, Inc. | Nouveau lacs de proteine cytosquelette associee a actine |
EP1550660A1 (fr) | 2002-09-12 | 2005-07-06 | Kirin Beer Kabushiki Kaisha | Derives d'isoquinoline d'inhibition des kinases et medicaments contenant ceux-ci |
US7495016B2 (en) | 2002-10-21 | 2009-02-24 | Irm Llc | Pyrrolidones with anti-HIV activity |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
PT1632477T (pt) | 2003-06-12 | 2017-04-04 | Astellas Pharma Inc | Derivado de benzamida ou seu sal |
AU2004268621C1 (en) | 2003-08-29 | 2011-08-18 | Exelixis, Inc. | c-Kit modulators and methods of use |
EP1689393A4 (fr) | 2003-10-06 | 2008-12-17 | Glaxo Group Ltd | Preparation d'azabenzimidazoles 1,7-disubstitues comme inhibiteurs de kinases |
DE10348023A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
JP2007008816A (ja) | 2003-10-15 | 2007-01-18 | Ube Ind Ltd | 新規イソキノリン誘導体 |
CN1863779B (zh) | 2003-10-15 | 2010-05-05 | 宇部兴产株式会社 | 吲唑衍生物 |
SE0400284D0 (sv) | 2004-02-10 | 2004-02-10 | Astrazeneca Ab | Novel compounds |
JP2005227441A (ja) | 2004-02-12 | 2005-08-25 | Konica Minolta Medical & Graphic Inc | 光熱写真画像形成材料 |
WO2005082890A1 (fr) | 2004-02-20 | 2005-09-09 | Smithkline Beecham Corporation | Nouveaux composes |
US20080096238A1 (en) | 2004-03-30 | 2008-04-24 | Alcon, Inc. | High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio |
DE102004017438A1 (de) | 2004-04-08 | 2005-11-03 | Bayer Healthcare Ag | Hetaryloxy-substituierte Phenylaminopyrimidine |
US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
JP2008503492A (ja) | 2004-06-17 | 2008-02-07 | スミスクライン・ビーチャム・コーポレイション | Rho−キナーゼの新規阻害剤 |
DK1607840T3 (da) | 2004-06-18 | 2015-02-16 | Tobii Technology Ab | Øjenstyring af et computerapparat |
KR100859891B1 (ko) | 2004-08-26 | 2008-09-23 | 화이자 인코포레이티드 | 단백질 키나제 억제제로서 거울상이성질체적으로 순수한아미노헤테로아릴 화합물 |
US20080132507A1 (en) | 2004-10-13 | 2008-06-05 | Eisai R&D Management Co., Ltd. | Hydrazide Derivatives |
UY29198A1 (es) | 2004-11-09 | 2006-05-31 | Cancer Rec Tech Ltd | Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones |
GB0425026D0 (en) | 2004-11-12 | 2004-12-15 | Biofocus Discovery Ltd | Compounds which bind to the active site of protein kinase enzymes |
CA2589271A1 (fr) | 2004-12-07 | 2006-06-15 | Locus Pharmaceuticals, Inc. | Inhibiteurs uree de map kinases |
CA2593718A1 (fr) | 2004-12-31 | 2007-05-31 | Gpc Biotech Ag | Composes de naphtyridine utilises comme inhibiteurs de rock |
AU2006204724A1 (en) | 2005-01-14 | 2006-07-20 | Millennium Pharmaceuticals, Inc. | Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity |
US20080287516A1 (en) | 2005-01-28 | 2008-11-20 | Irm Llc | Phenyl-Substituted Pyrrolidones |
EP1851197A2 (fr) | 2005-02-09 | 2007-11-07 | Microbia, Inc. | Derives de phenylazetidinone |
KR20080016604A (ko) | 2005-05-25 | 2008-02-21 | 와이어쓰 | 6-알킬아미노퀴놀린 유도체의 합성 방법 |
WO2007008926A1 (fr) | 2005-07-11 | 2007-01-18 | Aerie Pharmaceuticals, Inc. | Composes isoquinoliniques |
WO2007008942A2 (fr) | 2005-07-11 | 2007-01-18 | Aerie Pharmaceuticals, Inc. | Derives de [1-(pyridin-4-yl)-methylidene]-hydrazide d'acide phenylamino-acetique et composes associes en tant que modulateurs des kinases du recepteur couple a la proteine g pour le traitement de troubles oculaires |
US7893050B2 (en) | 2005-10-26 | 2011-02-22 | Asahi Kasei Pharma Corporation | Fasudil in combination therapies for the treatment of pulmonary arterial hypertension |
TW200738682A (en) | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
CN101340912A (zh) | 2005-12-22 | 2009-01-07 | 爱尔康研究有限公司 | 用于治疗rho激酶介导的疾病和病状的(吲唑-5-基)-吡嗪和(1,3-二氢-吲哚-2-酮)-吡嗪 |
AR057252A1 (es) | 2005-12-27 | 2007-11-21 | Alcon Mfg Ltd | Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares |
EP2420491B1 (fr) | 2005-12-30 | 2013-07-03 | Novartis AG | Dérivés de pipéridine 3,5-substitués en tant qu'inhibiteurs de rénine |
MX2008009557A (es) | 2006-01-27 | 2009-01-07 | Shanghai Hengrui Pharm Co Ltd | Inhibidores de la cinasa de proteina de la pirrolo [3,2-c] piridin-4-ona-2-indolinona. |
JP5476559B2 (ja) | 2006-02-10 | 2014-04-23 | 国立大学法人九州大学 | リン酸化酵素の新規基質ポリペプチド |
US7625927B2 (en) * | 2006-02-27 | 2009-12-01 | Alcon Research, Ltd. | Method of treating glaucoma |
CA2643044A1 (fr) | 2006-02-28 | 2007-09-07 | Amgen Inc. | Cinnoline et derives de quinoxaline en tant qu'inhibiteurs de phosphodiesterase 10 |
JP2007246466A (ja) | 2006-03-17 | 2007-09-27 | Osaka Univ | 中枢神経損傷に対する嗅粘膜移植にRhoキナーゼ阻害剤を用いた神経機能再建法 |
US8227480B2 (en) | 2006-06-08 | 2012-07-24 | Ube Industries, Ltd. | Indazole derivative having spiro ring structure in side chain |
US20090318485A1 (en) | 2006-07-20 | 2009-12-24 | Kalypsys, Inc. | Novel inhibitors of rho kinase |
JP2009544625A (ja) | 2006-07-20 | 2009-12-17 | メーメット・カーラマン | Rhoキナーゼのベンゾチオフェン阻害剤 |
EP2050449A4 (fr) | 2006-07-31 | 2010-10-06 | Senju Pharma Co | Préparation liquide aqueuse contenant un amide |
CA2664335C (fr) | 2006-09-20 | 2014-12-02 | Boehringer Ingelheim International Gmbh | Inhibiteurs de la rho-kinase |
CA2700988A1 (fr) | 2006-09-27 | 2008-05-08 | Surface Logix, Inc. | Inhibiteurs de la rho kinase |
WO2008044700A1 (fr) | 2006-10-11 | 2008-04-17 | Takeda Pharmaceutical Company Limited | INHIBITEUR DE LA GSK-3β |
US8949825B1 (en) | 2006-10-17 | 2015-02-03 | Manageiq, Inc. | Enforcement of compliance policies in managed virtual systems |
WO2008049000A2 (fr) | 2006-10-18 | 2008-04-24 | United Therapeutics Corporation | Thérapie de combinaison pour l'hypertension artérielle pulmonaire |
WO2008049919A2 (fr) | 2006-10-26 | 2008-05-02 | Devgen N.V. | Inhibiteurs de kinase |
US8071779B2 (en) | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
WO2008079945A2 (fr) | 2006-12-20 | 2008-07-03 | University Of South Florida | Inhibiteurs des rocks et leurs utilisations |
AR064420A1 (es) | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
RU2457203C2 (ru) | 2006-12-27 | 2012-07-27 | Санофи-Авентис | Замещенные циклоалкиламином производные изохинолона |
EP2114920A1 (fr) | 2006-12-27 | 2009-11-11 | Sanofi-Aventis | Dérivés d'isoquinoline et d'isoquinolinone substitués |
CN101616909B (zh) | 2006-12-27 | 2013-09-11 | 塞诺菲-安万特股份有限公司 | 作为Rho-激酶抑制剂的被取代的异喹啉和异喹啉酮衍生物 |
CN101573338B (zh) | 2006-12-27 | 2013-03-20 | 塞诺菲-安万特股份有限公司 | 环烷基胺取代的异喹诺酮和异喹啉酮衍生物 |
DE602007013295D1 (de) | 2006-12-27 | 2011-04-28 | Sanofi Aventis | Substituierte isochinoline und ihre verwendung als rho-kinase-inhibitoren |
DE602007010981D1 (de) | 2006-12-27 | 2011-01-13 | Sanofi Aventis | Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate |
MY151953A (en) | 2006-12-27 | 2014-07-31 | Sanofi Aventis | Cycloalkylamine substituted isoquinoline derivatives |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
WO2008105058A1 (fr) | 2007-02-27 | 2008-09-04 | Asahi Kasei Pharma Corporation | Sulfamides |
JP2010523689A (ja) | 2007-04-10 | 2010-07-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルココルチコイドミメティックス、その製造方法、医薬組成物及びその使用 |
RU2486181C2 (ru) | 2007-07-05 | 2013-06-27 | Эррэй Биофарма Инк. | Пиримидилциклопентаны как ингибиторы акт-протеинкиназ |
US8507524B2 (en) | 2007-11-16 | 2013-08-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette-transporters |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
KR20110042364A (ko) | 2008-08-15 | 2011-04-26 | 엔30 파머수티컬즈 엘엘씨 | 치료제로서 s-니트로소글루타티온 리덕타아제의 신규한 피롤 억제제 |
CA2764124C (fr) | 2009-06-19 | 2016-12-13 | D. Western Therapeutics Institute, Inc. | Derive d'isoquinoline substituee |
WO2011085351A2 (fr) | 2010-01-11 | 2011-07-14 | The Johns Hopkins University | Procédé de traitement de troubles liés à kcnq |
EP2663553B1 (fr) | 2010-09-01 | 2015-08-26 | Ambit Biosciences Corporation | Composés quinoléine et isoquinoléine en tant que modulateurs de jak |
AU2011327785A1 (en) | 2010-11-08 | 2013-03-07 | Healor Ltd. | Buffered ophthalmic compositions and methods of use thereof |
JPWO2012105674A1 (ja) * | 2011-02-04 | 2014-07-03 | 興和株式会社 | 緑内障予防又は治療のための薬物療法 |
JP2013035802A (ja) | 2011-08-10 | 2013-02-21 | D Western Therapeutics Institute Inc | 緑内障又は高眼圧症の予防又は治療剤 |
EP2671883A1 (fr) | 2012-06-05 | 2013-12-11 | Bioprojet | Nouveaux dérivés de 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azépines utilisés comme ligands du récepteur de l'histamine H4 |
JP2014019650A (ja) | 2012-07-13 | 2014-02-03 | Santen Pharmaceut Co Ltd | スルホンアミド化合物とタフルプロストの組み合わせ |
BR112015001959A2 (pt) | 2012-08-01 | 2017-07-04 | Merck Sharp & Dohme | composto, composição farmacêutica, métodos para melhorar os déficits cognitivos, para prevenir ou tratar déficits cognitivos distúrbios neurodegenerativos ou neuropsiquiátricos, para o tratamento ou prevenção de doenças inflamatórias e de dor neuropática, uso de um composto, e, processo para preparar um composto |
JP6325449B2 (ja) | 2012-10-12 | 2018-05-16 | 武田薬品工業株式会社 | シクロプロパンアミン化合物およびその用途 |
EP4218759A3 (fr) | 2013-03-15 | 2023-09-06 | Aerie Pharmaceuticals, Inc. | Traitment combiné |
AU2015289044A1 (en) | 2014-07-17 | 2016-12-08 | Cancer Research Technology Limited | Novel naphthryidines and isoquinolines and their use as CDK8/19 inhibitors |
US10227343B2 (en) | 2015-01-30 | 2019-03-12 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
US9770466B2 (en) | 2015-07-02 | 2017-09-26 | Veloce Biopharma, Llc | Ophthalmic composition and methods of use |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
JP2019529359A (ja) | 2016-08-19 | 2019-10-17 | アエリエ ファーマシューティカルズ インコーポレイテッド | ベータ−アミノ−イソキノリニルアミド化合物 |
US11389441B2 (en) | 2016-08-31 | 2022-07-19 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
AU2018243687C1 (en) | 2017-03-31 | 2020-12-24 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
CA3095730A1 (fr) | 2018-03-30 | 2019-10-03 | Aerie Pharmaceuticals, Inc. | Sels de mono-(acide) de 6-aminoisoquinolines et leurs utilisations |
CA3112391A1 (fr) | 2018-09-14 | 2020-03-19 | Aerie Pharmaceuticals, Inc. | Composes d'amide aryl cyclopropyl-amino-isoquinolinyl |
-
2014
- 2014-03-14 EP EP23156661.3A patent/EP4218759A3/fr active Pending
- 2014-03-14 CA CA2905089A patent/CA2905089C/fr active Active
- 2014-03-14 EP EP18206195.2A patent/EP3461484B9/fr active Active
- 2014-03-14 AU AU2014228790A patent/AU2014228790B2/en active Active
- 2014-03-14 PT PT202076576T patent/PT3811943T/pt unknown
- 2014-03-14 EP EP23199180.3A patent/EP4335507A2/fr active Pending
- 2014-03-14 HU HUE20207657A patent/HUE061618T2/hu unknown
- 2014-03-14 US US14/213,961 patent/US9415043B2/en active Active
- 2014-03-14 ES ES14719999T patent/ES2776199T3/es active Active
- 2014-03-14 PL PL20207657.6T patent/PL3811943T3/pl unknown
- 2014-03-14 CN CN201811109366.7A patent/CN109528721B/zh active Active
- 2014-03-14 FI FIEP20207657.6T patent/FI3811943T3/fi active
- 2014-03-14 EP EP14719999.6A patent/EP2976080B1/fr active Active
- 2014-03-14 DK DK20207657.6T patent/DK3811943T3/da active
- 2014-03-14 US US14/213,940 patent/US20140275160A1/en not_active Abandoned
- 2014-03-14 CN CN201480027763.3A patent/CN105263494A/zh active Pending
- 2014-03-14 WO PCT/US2014/029335 patent/WO2014144781A1/fr active Application Filing
- 2014-03-14 ES ES18206195T patent/ES2852377T3/es active Active
- 2014-03-14 EP EP20207657.6A patent/EP3811943B1/fr active Active
- 2014-03-14 JP JP2016503064A patent/JP2016515520A/ja not_active Withdrawn
- 2014-03-14 ES ES20207657T patent/ES2942898T3/es active Active
- 2014-03-14 CN CN201910531443.6A patent/CN110396085A/zh active Pending
-
2016
- 2016-04-29 US US15/142,461 patent/US9849122B2/en active Active
- 2016-08-15 US US15/236,625 patent/US9931336B2/en active Active
-
2017
- 2017-06-19 US US15/627,238 patent/US9993470B2/en active Active
-
2018
- 2018-02-21 US US15/901,361 patent/US10568878B2/en active Active
- 2018-04-30 AU AU2018202990A patent/AU2018202990C1/en active Active
- 2018-04-30 AU AU2018202965A patent/AU2018202965B2/en active Active
- 2018-05-03 US US15/970,635 patent/US10588901B2/en active Active
-
2019
- 2019-01-28 JP JP2019011857A patent/JP2019094339A/ja not_active Withdrawn
- 2019-12-30 US US16/730,015 patent/US11020385B2/en active Active
-
2020
- 2020-02-03 US US16/780,294 patent/US20200276179A1/en not_active Abandoned
- 2020-05-08 JP JP2020082445A patent/JP2020125355A/ja not_active Withdrawn
- 2020-06-05 JP JP2020098292A patent/JP2020143163A/ja not_active Withdrawn
- 2020-06-15 AU AU2020203976A patent/AU2020203976A1/en not_active Abandoned
- 2020-12-22 JP JP2020212021A patent/JP2021046439A/ja not_active Withdrawn
-
2021
- 2021-04-23 US US17/238,550 patent/US11185538B2/en active Active
- 2021-04-23 US US17/238,554 patent/US11197853B2/en active Active
- 2021-05-10 NL NL301101C patent/NL301101I2/nl unknown
- 2021-12-07 US US17/544,648 patent/US20220088000A1/en not_active Abandoned
-
2022
- 2022-12-20 JP JP2022202875A patent/JP2023030072A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090186917A1 (en) * | 2008-01-17 | 2009-07-23 | Aerie Pharmaceuticals, Inc. | 6-And 7-amino isoquinoline compounds and methods for making and using the same |
US20100280011A1 (en) * | 2009-05-01 | 2010-11-04 | Delong Mitchell A | Dual mechanism inhibitors for the treatment of disease |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10624882B2 (en) | 2006-09-20 | 2020-04-21 | Aerie Pharmaceuticals, Inc. | Rho kinase inhibitors |
US10899714B2 (en) | 2007-01-10 | 2021-01-26 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US10472327B2 (en) | 2007-01-10 | 2019-11-12 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US9890123B2 (en) | 2007-01-10 | 2018-02-13 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US10882840B2 (en) | 2008-07-25 | 2021-01-05 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US11021456B2 (en) | 2008-07-25 | 2021-06-01 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US9884840B2 (en) | 2008-07-25 | 2018-02-06 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US9512101B2 (en) | 2008-07-25 | 2016-12-06 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US10112920B2 (en) | 2008-07-25 | 2018-10-30 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US10532993B2 (en) | 2008-07-25 | 2020-01-14 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US11028081B2 (en) | 2009-05-01 | 2021-06-08 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US9951059B2 (en) | 2009-05-01 | 2018-04-24 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US10654844B2 (en) | 2009-05-01 | 2020-05-19 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US11618748B2 (en) | 2009-05-01 | 2023-04-04 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US10174017B2 (en) | 2009-05-01 | 2019-01-08 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US10316029B2 (en) | 2009-05-01 | 2019-06-11 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US11020385B2 (en) | 2013-03-15 | 2021-06-01 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US9849122B2 (en) | 2013-03-15 | 2017-12-26 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US9415043B2 (en) | 2013-03-15 | 2016-08-16 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US10568878B2 (en) | 2013-03-15 | 2020-02-25 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US10588901B2 (en) | 2013-03-15 | 2020-03-17 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US11197853B2 (en) | 2013-03-15 | 2021-12-14 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US9993470B2 (en) | 2013-03-15 | 2018-06-12 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US11185538B2 (en) | 2013-03-15 | 2021-11-30 | Aerie Pharmaceuticals, Inc. | Compositions for treating glaucoma or reducing intraocular pressure |
US9931336B2 (en) | 2013-03-15 | 2018-04-03 | Aerie Pharmaceuticals, Inc. | Combination therapy |
WO2016029191A2 (fr) | 2014-08-22 | 2016-02-25 | Auckland Uniservices Limited | Modulateurs de canaux |
US10465188B2 (en) | 2014-08-22 | 2019-11-05 | Auckland Uniservices Limited | Channel modulators |
WO2017086941A1 (fr) * | 2015-11-17 | 2017-05-26 | Aerie Pharmaceuticals, Inc. | Procédé de préparation d'inhibiteurs de kinase et de leurs intermédiaires |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
CN108601355A (zh) * | 2015-11-17 | 2018-09-28 | 爱瑞制药公司 | 制备激酶抑制剂及其中间体的方法 |
US10550087B2 (en) | 2015-11-17 | 2020-02-04 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
US11389441B2 (en) | 2016-08-31 | 2022-07-19 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
US11590123B2 (en) | 2016-08-31 | 2023-02-28 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
US11707460B2 (en) | 2016-08-31 | 2023-07-25 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
US10858339B2 (en) | 2017-03-31 | 2020-12-08 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US11312700B2 (en) | 2017-03-31 | 2022-04-26 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US11427563B2 (en) | 2018-09-14 | 2022-08-30 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US11891376B2 (en) | 2018-09-14 | 2024-02-06 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11197853B2 (en) | Combination therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AERIE PHARMACEUTICALS, INC., NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOPCZYNSKI, CASEY;LIN, CHENG-WEN;STURDIVANT, JILL MARIE;AND OTHERS;REEL/FRAME:033157/0469 Effective date: 20140617 |
|
AS | Assignment |
Owner name: DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER Free format text: SECURITY INTEREST;ASSIGNOR:AERIE PHARMACEUTICALS, INC.;REEL/FRAME:033726/0043 Effective date: 20140908 Owner name: DEERFIELD SPECIAL SITUATIONS FUND, L.P., NEW YORK Free format text: SECURITY INTEREST;ASSIGNOR:AERIE PHARMACEUTICALS, INC.;REEL/FRAME:033726/0043 Effective date: 20140908 Owner name: DEERFIELD INTERNATIONAL MASTER FUND, L.P., NEW YOR Free format text: SECURITY INTEREST;ASSIGNOR:AERIE PHARMACEUTICALS, INC.;REEL/FRAME:033726/0043 Effective date: 20140908 Owner name: DEERFIELD PARTNERS, L.P., NEW YORK Free format text: SECURITY INTEREST;ASSIGNOR:AERIE PHARMACEUTICALS, INC.;REEL/FRAME:033726/0043 Effective date: 20140908 Owner name: DEERFIELD PRIVATE DESIGN FUND III, L.P., NEW YORK Free format text: SECURITY INTEREST;ASSIGNOR:AERIE PHARMACEUTICALS, INC.;REEL/FRAME:033726/0043 Effective date: 20140908 Owner name: DEERFIELD MANAGEMENT COMPANY, L.P., AS AGENT, NEW Free format text: SECURITY INTEREST;ASSIGNOR:AERIE PHARMACEUTICALS, INC.;REEL/FRAME:033726/0043 Effective date: 20140908 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: AERIE PHARMACEUTICALS, INC., NORTH CAROLINA Free format text: RELEASE BY SECURED PARTY;ASSIGNORS:DEERFIELD PARTNERS, L.P.;DEERFIELD PRIVATE DESIGN FUND III, L.P.;DEERFIELD SPECIAL SITUATIONS FUND, L.P.;AND OTHERS;REEL/FRAME:046431/0600 Effective date: 20180723 |